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Abstract 
Ovarian cancer remains a major cause of cancer mortality in women, with 
relatively poor understanding of disease aetiology at the molecular level and only 
limited treatment options. This is exacerbated by the asymptomatic nature of the 
disease, such that women with ovarian cancer typically present with advanced-stage 
disease, when the cancer has already spread through the peritoneum and sometimes 
to distant metastatic sites. Therefore, further investigation of the biology of ovarian 
cancer is an important area of research to underpin improvements in clinical 
outcomes. 
Cytokines are known to play a pivotal role in a diverse range of 
developmental processes and cellular responses via specific cell surface receptors. 
The IL-6R family of cytokine receptors exerts a myriad of functions, including in 
blood and immune cell development, neurogenesis and appetite regulation, mediated 
via several intracellular signaling pathways, including the so-called ‘JAK-STAT’ 
pathway. Dysregulation of IL-6R family-JAK-STAT signaling has been shown to 
contribute to a number of diseases, including cancer. This Thesis describes studies 
aimed at investigating the role of the IL-6R family in ovarian cancer.  
Chapter Three assessed the expression of IL-6R components and their ligands 
in a panel of ovarian cancer cell lines and patient samples. Broad expression of IL-
6R family receptors and their corresponding ligands was observed, including in the 
same samples, suggesting possible autocrine activation. Two of the IL-6R family 
receptors were chosen for further study: the Granulocyte colony-stimulating factor 
receptor (G-CSFR), which was predominantly expressed in high-grade ovarian 
epithelial tumor samples, and Leptin receptor (OBR), which was expressed in a 
subset of ovarian cancer cell lines. 
 vii 
 
G-CSF is a key regulator of both normal and emergency hematopoiesis, and 
is used clinically to aid hematopoietic recovery following ablative therapies for a 
variety of solid tumors, including ovarian cancer. Chapter Four demonstrated that 
stimulation of G-CSFR-positive ovarian epithelial cancer cells with G-CSF led to 
increased migration and survival, including a resistance to chemotherapy-induced 
apoptosis. The effects of G-CSF were shown to be mediated via the downstream 
JAK2/STAT3 pathway.  
Leptin is a multifunctional peptide hormone that functions in appetite 
regulation, bone formation and reproductive function, with signaling via its receptor 
(OBR) previously implicated in cancer cell migration, proliferation and survival. 
Studies in Chapter Five showed that stimulation of OBR-expressing ovarian cancer 
cells with Leptin caused a variety of cellular responses, which included increased 
migration and survival, of several cell types, mesenchymal to epithelial transistion 
(MET) in a teratocarcinoma cell line . Each of these phenotypes was shown to be 
mediated by the JAK2/STAT3 pathway.  
Collectively, the studies described in this Thesis suggest that signaling via IL-
6R family members  significantly impacted on ovarian cancer cells. G-CSF was 
shown to influence migration and survival on G-CSFR-positive cancers, which has 
implications for its current therapeutic use in ovarian cancer. In contrast, Leptin was 
demonstrated to exert differential effects on ovarian cancer cells, which also has 
potential clinical ramifications. These results suggest that assessment of IL-6R 
family expression represents a potential prognostic tool in determining appropriate 
therapy for ovarian cancer patients. 
 
 viii 
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1.1 Introduction 
Ovarian cancer is the most lethal gynaecological cancer, with approximately 
200,000 new cases diagnosed each year globally, and a greater than 60% mortality 
rate within five years (NBOCC, 2011). This is partly due to the asymptomatic nature 
of the disease, such that the primary tumor has often already spread at the time of 
diagnosis (Lengyel, 2010). However, there is also a poor understanding of disease 
etiology at the molecular level, which continues to hamper targeted therapeutic 
development. 
1.2 Biology of ovarian cancer 
1.2.1 Types of ovarian cancer 
Ovarian cancer is not a single disease, but rather a spectrum of malignancies 
exhibiting varied histopathology and biology (Chen et al., 2003). Ovarian cancers are 
grouped into three major categories based on the cells from which they originate, 
namely: germ cells, stromal cells and epithelial cells (Soslow, 2008) (Figure 1.1). 
1.2.1.1 Germ cell tumors 
Germ cell tumors are derived from oocytes within the ovaries, and represent 
approximately 10%-15% of all ovarian cancers (Auersperg et al., 2001). They tend to 
occur in women who are in their early 20s. Specific markers such as beta-human 
chorionic gonadotropin (ß-HCG) and alpha-fetoprotein (FP) are able to be used to 
aid in diagnosis (Kobel et al., 2008). 
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Figure 1.1: Model of biology of ovarian cancer and its progression  
Diagrammatic representation of types of ovarian cancer and their progression, 
indicating key phenotypes of cancers, namely survival, proliferation and 
invasion/migration. 
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1.2.1.2 Stromal cell tumors 
Stromal (or ‘Sex cord’) tumors are formed from cells of the stromal 
mesenchyme/sex-cord within the ovary. They represent about 5% of all ovarian 
cancers and more commonly seen in postmenopausal women (Auersperg et al., 
2001). These tumors contain immature fibroblasts and connective tissue-forming 
cells, with granulosas being the most prevalent type (Roth, 2006). These patients 
usually show symptoms such as vaginal bleeding and elevated blood levels of the 
tumor markers in particular a peptide hormone inhibin, which prevents the release of 
follicle stimulating hormone (FSH) (Jamieson and Fuller, 2012). This probably 
contributes to the generally earlier diagnosis of patients with stromal cell tumors, 
with concomitant improvement in prognosis for this cohort of patients (Sehouli et al., 
2004). 
1.2.1.3 Epithelial ovarian cancer 
Epithelial ovarian cancer (EOC) is the most common form of this disease, 
representing about 80% of all cases. EOC consists of distinct histological subtypes: 
70% serous histology (cells resembling the lining of the fallopian tube), 15% 
endometrioid (cells resembling the endometrium), 10% clear cell (cells with clear 
cytoplasm) and 5% mucinous (cells resembling endocervical endothelium) (Kurian et 
al., 2005, Marquez et al., 2005, Bell, 2005). Each EOC subtype has identifiable 
precursor lesions, with some specific genetic alterations identified (Breedlove and 
Busenhart, 2005, Chien et al., 2007), with most EOC originating from the malignant 
transformation of the ovarian surface epithelium (OSE) (Dubeau, 2008).  
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1.2.2 Ovarian cancer progression 
There is a growing consensus that ovarian cancer, like many other cancers, is a stem 
cell disease in which a small population of cells has acquired the ability to both self-
renew as well as generate the cell types characteristic of that tumor (Ponnusamy and 
Batra, 2008). During the transformation process, ovarian cancer cells acquire a 
number of properties, such as increased cell proliferation, survival and migration. 
There are specific changes in cell-cell and cell-extracellular matrix (ECM) 
interactions, with increased proteolysis and ECM degradation observed. This 
culminates in the shedding of tumor cells into the peritoneum where they survive in 
an anchorage-independent manner as cellular aggregates or spheroids, until they 
attach to a suitable secondary site for further growth (Shield et al., 2007, Shield et al., 
2009). Women with ovarian cancer typically present with advanced-stage disease, 
when the cancer has already spread throughout the peritoneum, and in some cases, to 
distant metastatic sites. With aggressive surgery supplemented with paclitaxel and 
platinum-based chemotherapy, most patients initially return to a state of microscopic 
disease with minimal residual tumor. However, this is usually short-lived with 
recurrent disease characterised by increased metastatic behaviour and acquisition of 
drug-resistance to multiple types of chemotherapy, due – at least in part – to 
increased activity of the ATP-binding cassette (ABC) drug transporters, enhanced 
DNA repair and reduced apoptosis (Gottesman, 2002). Only ~30% of patients with 
recurrent disease survive for >5 years (Soslow, 2008). 
1.2.3 Therapies in ovarian cancer 
Current therapies for ovarian cancer include cytoreductive surgery followed 
by combination platinum/taxane-based chemotherapy (McGuire et al., 1996). 
Patients initially respond to chemotherapy but eventually develop resistance thereby 
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leading to poor survival rate (Ozols, 2003, Agarwal and Kaye, 2003). This 
exemplifies the need to identify new therapeutic targets to treat ovarian cancer 
patients. Studies have shown that several factors influence the autocrine production 
of cytokines and growth factors thereby influencing drug resistance to these patients 
and activation of numerous signaling pathways could contribute to this resistance 
(Wang et al., 2010). Therefore, targeting these cytokines and growth factors and their 
signaling pathway may provide new therapeutic opportunities to treat ovarian cancer 
patients.  
1.3 Growth factors and cytokines 
1.3.1 Growth factors in ovarian cancer 
Growth factors are proteins that bind to receptor tyrosine kinases on the cell 
surface to regulate a variety of cellular responses, such as activating cellular 
proliferation and/or differentiation (Owens et al., 1991). Many different families of 
growth factor and their receptors exist. Their exact functions vary: for example, bone 
morphogenic proteins stimulate bone cell differentiation (Overman et al., 2013), 
while fibroblast growth factors and vascular endothelial growth factors stimulate 
blood vessel differentiation (angiogenesis) (Hoeben et al., 2004, Yun et al., 2010). 
Many factors and/or receptors are seen to be over expressed in malignant cells. One 
of the most widely studied growth factors in the context of ovarian cancer 
progression is the epidermal growth factor receptor (EGFR) (Langdon and Smyth, 
1998, Langdon et al., 2009).  
1.3.1.1 Epidermal growth factor receptor 
The EGF receptor (EGFR) is a member of the ErbB family of receptors 
(Zhang et al., 2007). Binding of EGF to its receptor complex leads to the activation 
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of numerous downstream signaling pathways that are involved in tumor cell growth 
and survival (Citri and Yarden, 2006, Linggi and Carpenter, 2006). EGFR expression 
is generally recognized to have a deleterious impact on the clinical outcome of 
cancer patients whereby its expression is associated with invasive tumor cells 
(Condeelis et al., 2005). This has led to the development of targeted therapeutics 
(Wieduwilt and Moasser, 2008, Mendelsohn and Baselga, 2006, Zhang et al., 2007). 
Epithelial ovarian cancer has been shown to express EGFR (Auersperg et al., 
2001, Conti et al., 2006, Lafky et al., 2008), with EGF stimulation leading to 
phenotypic changes in the ovarian cancer cells (Ben-Ami et al., 2006). Studies have 
also shown that patients expressing EGFR have a poor survival rate compared to 
those who do not express the receptor (Tingulstad et al., 2003).  
EGFR in ovarian cancer correlates with increased tumor growth rate 
(Siemens and Auersperg, 1988), with activation of genes associated with tumor 
invasion and metastasis, which can be blocked with specific inhibitors (Barbolina et 
al., 2009, Cowden Dahl et al., 2008, Hudson et al., 2009). EGFR activation can also 
result in an epithelial to mesenchymal transition with the disruption of E-cadherin 
and degradation of extracellular matrix by metalloproteinase enzymes (Huber et al., 
2005, Barbolina et al., 2009, Sabbah et al., 2008). Therefore, targeting EGFR in 
ovarian cancer represents an attractive therapy. 
1.3.1.2 Cytokines in ovarian cancer 
Cytokines are small polypeptides released from cells to regulate the activities 
of other cells via interactions with specific cytokine receptors expressed on their 
surface (Leonard and Lin, 2000). They have a wide range of functions, including the 
ability to stimulate proliferation, differentiation, survival and activation (Kurian et 
al., 2005, Obata et al., 1997).  
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As many as 16 different cytokines have been found to be expressed in normal 
ovaries, along with many of the corresponding receptors (Burke et al., 1996). Indeed 
virtually all of the cytokines and their receptors found in ovarian tumors are also 
found in the normal ovary (Nash et al., 1999). However, there appears to be a shift in 
the expression of these cytokines and their receptor, with significantly increased 
expression of certain cytokines and receptors observed in ovarian cancer. While their 
specific physiological roles remain poorly understood they appear to act – along with 
growth factors such as EGF – to enhance key phenotypes associated with tumor 
progression, such as proliferation, survival, migration or chemo-resistance (Shield et 
al., 2007).  
1.4 The IL-6R family 
1.4.1 Structure and function 
Of particular relevance to ovarian cancer are cytokines that act via members 
of the so-called interleukin-6 receptor or “IL-6R” family of cytokine receptors 
(Figure 1.2). The core members of this family employ a ligand-specific receptor  
chain in combination with a shared receptor chain, glycoprotein 130 (GP130), and 
sometimes a third receptor chain. However, also in this family are the GP130-related 
granulocyte colony-stimulating factor receptor (G-CSFR) and obesity gene receptor 
(OBR), both of which form homomeric complexes (Devos et al., 1997, Hiraoka et 
al., 1994). 
Individual IL-6R family members have distinct functions: for example, IL-6R 
mediates immune, hematopoietic and hepatic responses (Kishimoto,2005),  
oncostatin M receptor (OSMR) has a role in the differentiation and survival of neural 
and hematopoietic cells (Morikawa, 2005), leukemia inhibitory factor receptor 
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Figure 1.2: The interleukin-6 receptor family 
The IL-6R family members, with their constituent receptor chains. 
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(LIFR) functions in stem cell maintenance, neural and hematopoietic development 
(Taupin et al., 1998, Kurzrock et al., 1991, Graf et al., 2011), G-CSFR plays a key 
role in granulocytic development, hematopoietic stem cell mobilization and myeloid 
cell migration (Lieschke et al., 1994, Liongue et al., 2009a, Liongue et al., 2009b), 
while OBR, the receptor for the cytokine Leptin, functions in the regulation of 
energy homeostasis (Cottrell and Mercer, 2012). The expression of these receptors 
and their ligands is tightly controlled to ensure these processes occur in a non-
pathological manner.  
1.4.2 Downstream signaling 
Within the IL-6R family, the utilization of GP130 or related receptor chains 
to transduce intracellular signals means that similar downstream pathways are 
activated in each case (O'Sullivan et al., 2007). These include the mitogen-activated 
protein kinase (MAPK) including ERK1/2 or p38 or JNK, phosphatidyl-inositol 3-
kinase (PI3K), and Janus kinase-Signal transducer and activator of transcription 
(JAK/STAT) pathways (Imada and Leonard, 2000, Hong et al., 2007, Heinrich et al., 
2003, Heinrich et al., 1998). JAK tyrosine kinases are constitutively associated with 
IL-6R family members and are activated following ligand binding (Heinrich et al., 
2003, Heinrich et al., 1998, Calo et al., 2003). This, in turn, leads to tyrosine 
phosphorylation of the receptor forming docking sites for signaling molecules, 
including STATs, which in turn also become activated. While other JAKs and 
STATs may also be activated, virtually all members of the IL-6R family utilise the 
JAK1-2/STAT3 signaling pathway as a core mechanism for mediating their 
downstream effects (Rawlings et al., 2004). Phosphorylation of STAT3 causes it to 
dimerize and translocate from the cytoplasm to the nucleus where it initiates changes 
in the transcription of a number of genes, including those affecting growth, 
Chapter 1 Literature Review 
 
13 
 
differentiation, and survival (Heinrich et al., 1998, Levy and Lee, 2002, Yu and Jove, 
2004). Although the full spectrum of STAT3 target genes is yet to be defined, several 
have been identified that contribute to specific cell phenotypes (Figure 1.3) 
(Dijkgraaf et al., 2012). These include pro-proliferative genes Cyclin D1 and c-
MYC, the anti-apoptotic genes BCL-2 and Survivin, functional genes such as MMPs, 
ICAM, Integrins and CRP, as well as the key negative regulator Suppressors of 
Cytokine Signaling (SOCS) 3 (Kim et al., 2007). The latter acts in concert with 
tyrosine phosphatases and other regulatory proteins to extinguish signaling from IL-
6R family members (Wormald and Hilton, 2004) 
1.5 Role of the IL-6R family in ovarian cancer 
 There is increasing evidence that signaling via the IL-6R family may play a 
significant role in the progression of ovarian and other cancers.  
1.5.1 IL-6/IL-6R  
 IL-6 is a potent, pleiotropic cytokine. It acts via a receptor complex consisting 
of the ligand-binding IL-6Rα chain and the signal-transducing GP130 chain, both of 
which are widely expressed (Heinrich et al., 2003, Heinrich et al., 1998). There are 
two forms of IL-6Rα: a membrane-bound form with low affinity for IL-6 that forms 
a complex with GP130 after ligand binding, and a soluble form (sIL-6R) that binds 
with IL-6 extracellularly and then associates with GP130 molecules on target cells 
(Scheller et al., 2006, Imada and Leonard, 2000). IL-6R signaling is involved in 
hepatic acute phase response and immune responses and is also known to contribute 
to follicle development in normal ovaries (Machelon et al., 1994, Lidor et al., 1993). 
In addition, IL-6R signaling plays numerous roles in the inflammatory response 
(Hong et al., 2007, Nilsson et al., 2005). 
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Figure 1.3: IL-6R family signaling in ovarian cancer. 
 
Signaling from the IL-6R family of receptors (autocrine or paracrine) via JAK1-
2/STAT3 and its impact on expression of target genes involved in the key malignant 
phenotypes of proliferation, survival and migration/invasion, as well as negative 
feedback. 
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 IL-6 has been implicated in a wide range of cancers, such as multiple 
myeloma (Fulciniti et al., 2009, Shi et al., 2008, Lauta, 2001), endometrial cancer 
(Bellone et al., 2005), lung cancer (Songur et al., 2004), colorectal cancer (Belluco et 
al., 2000), renal cell carcinoma (Altundag et al., 2005, Negrier et al., 2004), cervical 
cancer (Wei et al., 2003) and breast cancer (Garcia-Tunon et al., 2005, Salgado et al., 
2003). Overexpression of both IL-6 and its receptors (IL-6R and sIL-6R) in cancer 
patients has been associated with poor clinical outcomes (Trikha et al., 2003, Hong et 
al., 2007, Chen et al., 1999, Kishimoto, 2005). IL-6 is also known to directly 
promote tumor cell attachment, proliferation and migration through the activation of 
several downstream signaling pathways such as the JAK/STAT and MAPK cascades 
(Kamimura et al., 2003, Heinrich et al., 1998, Steelman et al., 2004). Other studies 
have shown that the high expression of IL-6 and its receptors in breast tumor 
increases BCL-2 expression, thus altering the balance of proliferation and apoptosis 
toward neoplastic cell proliferation (Garcia-Tunon et al., 2005). The unchecked 
production of IL-6 can also lead to chronic inflammation, which is implicated in 
many types of cancer (Ayre, 1956, Dalgleish and O'Byrne, 2002, Farrow and Evers, 
2002, Nelson et al., 2004, Schwartsburd, 2003). 
 Several preclinical studies have explored the role of IL-6 in ovarian cancer. 
IL-6 can be produced directly by EOCs, or through secondary inflammation (Watson 
et al., 1990, Wu et al., 1992). Increased levels of IL-6 are associated with poor 
prognosis (Berek et al., 1991, Stone et al., 2012) and is associated with subtypes with 
poorer outcomes (Anglesio et al., 2011). IL-6 can act in a number of ways to 
augment ovarian cancer progression. Through its actions on endothelial cells it can 
stimulate angiogenesis (Nilsson et al., 2005, Coward et al., 2011) and blunt the 
potency of chemotherapeutic agents (Lo et al., 2011), as well as act on macrophages 
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to polarise them toward the immunosuppressive M2 phenotype (Duluc et al., 2007). 
However, it can also act directly on ovarian cancer cells to enhance migration, 
invasion and attachment (Obata et al., 1997, Colomiere et al., 2009, Wang et al., 
2012), mediate anchorage-independent growth (Wang et al., 2012) and enhance 
chemoresistance by increased expression of multi drug resistance pumps and anti-
apoptotic genes (Duan et al., 2006, Wang et al., 2010).  
Studies have shown that there is an increased expression of IL-6 and different 
IL-6R isoforms in ovarian tumors, and that both tumor and host cells contribute to 
soluble IL-6R expression in the tumor environment (Robinson-Smith et al., 2007, 
Rath et al., 2010, Wang et al., 2012, Colomiere et al., 2009). Increased levels of the 
soluble form of the receptor are also associated with malignant ovarian cancer, 
generated either via alternate splicing or increased expression of sheddases that can 
act on the full-length receptor. This can mediate increased proliferation and other 
effects in tumor cells, as well as adjacent stromal cells or peritoneal cells (Rath et al., 
2010).  One study showed that an ovarian cancer cell line positive for IL-6R 
expression showed an approximately 50% increased rate of tumor formation in mice 
compared with cells lacking IL-6R expression. The tumors which developed also 
showed elevated expression of IL-6R (Rath et al., 2010). IL-6 is also known to be 
constitutively secreted from the ovarian cancer microenvironment and high plasma 
levels are known to be correlated with poor prognosis (Lutgendorf et al., 2008, 
Scambia et al., 1995). Production of IL-6 has been shown to be increased in the EOC 
cell lines SKOV3 and OVCA433 after stimulation with EGF (Colomiere et al., 
2009), and in advanced-stage epithelial ovarian cancer via the NFκB pathway 
(Alberti et al., 2012), indicating cross-talk of other pathways with cytokine signaling. 
There have also been a number of studies that have reported an increased production 
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of IL-6 in paclitaxel resistant ovarian cancer cells and also in the serum and ascites of 
patients (Penson et al., 2000, Duan et al., 1999, Scambia et al., 1995, Berek et al., 
1991). These studies suggest that targeting IL-6/IL-6R could provide an effective 
therapeutic target in ovarian cancer. 
1.5.2 G-CSF/G-CSFR  
G-CSF is a 25 kD secreted glycoprotein that binds to a single-chain receptor, 
G-CSFR, closely related to GP130, but which forms a homodimeric complex 
(Liongue et al., 2009b). The G-CSFR is expressed on a range of hematopoietic cells, 
including mature neutrophilic granulocytes, myeloid progenitors, hematopoietic stem 
cells, monocytes and lymphocytes, as well non-hematopoietic tissues, including 
cardiomyocytes, neuronal precursors, endothelial cells and placental tissue (Touw 
and van de Geijn, 2007). Its principal role is in the mobilization of hematopoietic 
stem cells and production of neutrophils during “emergency hematopoiesis” 
(Panopoulos and Watowich, 2008). These properties have seen G-CSF commonly 
used in the clinic to increase the production of neutrophils in patients with 
chemotherapy induced neutropenia (Nakamae-Akahori et al., 2006, Roberts, 2005). 
The G-CSFR has previously been implicated in a diverse range of 
malignancies. For example, a significant proportion of invasive bladder carcinomas 
have been shown to express both G-CSF and G-CSFR, with subsequent autocrine 
signaling contributing to their proliferation and survival in vitro (possibly via 
STAT3), as well as the size of their induced tumors in vivo (Chakraborty et al., 
2004). G-CSF was also shown to stimulate the proliferation and migration of tumor 
cells derived from patients with head and neck squamous cell carcinoma, which 
could be blocked with neutralizing antibodies. Interestingly, while G-CSFR-positive 
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tumors grew at a slower rate, increased invasion and angiogenesis, coupled with 
decreased necrosis, was observed (Gutschalk et al., 2006). Functional G-CSFR 
complexes have also been identified on other solid tumors (Westphal et al., 2002).  
The role of G-CSF/G-CSFR in ovarian cancer has remained controversial. 
Broad expression of the G-CSFR has been reported in ovarian cancer cells 
(Brandstetter et al., 1998, Ninci et al., 2000, Savarese et al., 2001, Brandstetter et al., 
2001). There was often co-expression of G-CSF in these cells, or in neighbouring 
stromal tissue, meaning both autocrine and paracrine activation is possible. The 
clinical significance of G-CSF expression remains unclear, with one study showing it 
was an adverse prognostic factor if part of a paracrine loop (Savarese et al., 2001), 
but another suggesting it did not correlate with prognosis (Munstedt et al., 2010). G-
CSF was able to support proliferation in certain primary ovarian cancer cells and cell 
lines (Spinner et al., 1995, Brandstetter et al., 1998), but in others it inhibited 
proliferation (Spinner et al., 1995) or had no effect (Savarese et al., 2001, 
Brandstetter et al., 2001). G-CSF was found to enhance EGF-mediated mitogenesis 
in the G-CSFR-positive cell line OVCAR-3 (Savarese et al., 2001), suggesting cross-
talk with growth factor receptor signaling was possible.  
1.5.3 Leptin/OBR 
Leptin, a 16kDa protein, signals via OBR (Tartaglia, 1997). Like G-CSFR, 
OBR does not form oligomers with GP130 but signals directly as a homodimer 
(Nakashima et al., 1997), although it initiates similar signaling pathways to other IL-
6R receptors, namely the JAK/STAT, MAPK and PI3K pathways (Ghilardi et al., 
1996, Villanueva and Myers, 2008). OBR signaling has a wide variety of roles in 
regulating energy metabolism, appetite regulation, bone formation and angiogenesis 
(Bouloumie et al., 1998, Huang and Li, 2000, Sierra-Honigmann et al., 1998). 
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However, it also has important roles in cancer cell proliferation, invasion and 
metastasis, including in breast, prostate, hepato and endometrial cancers 
(Somasundar et al., 2004, Saxena et al., 2007a, Saxena et al., 2007b, Sharma et al., 
2006). In the case of breast cancer, there have been extensive studies on Leptin-
induced Epithelial-to-Mesenchymal transition via the Wingless Type 1 (WNT1) 
signaling pathway (Yan et al., 2012), leading to increased cell proliferation (Yin et 
al., 2004, Hu et al., 2002). Other studies have reported proliferative and anti-
apoptotic effects of Leptin in prostate and breast cancers via STAT3 activation 
(Wazir et al., 2012, Hoda et al., 2012).  
The role of Leptin/OBR signaling in ovarian cancer remains less clear. Both 
Leptin and its receptor are expressed in normal ovary (Loffler et al., 2001), but OBR 
overexpression represents a poor prognostic factor for epithelial ovarian cancer 
(Uddin et al., 2009). OBR expression was found in three ovarian cancer cell lines, 
SKOV-3, BG-1 and OVCAR-3, but only the BG-1 cell line showed an increased rate 
of proliferation in response to Leptin (Choi et al., 2005). However, another study 
showed Leptin could stimulate cell proliferation and inhibit apoptosis in the 
OVCAR-3 cell line (Ptak et al., 2013). Recent studies have confirmed that Leptin can 
stimulate cell growth and inhibit apoptosis in OVCAR-3 cell line through increased 
Cyclin D1 and Mcl-1 expression, in this case via the activation of the MEK/ERK1/2 
and PI3K/Akt signaling pathways (Chen et al., 2013). Interestingly, while the short 
forms of OBR are expressed in all EOCs, the expression of the long forms of the 
receptor is more variable (Choi et al., 2005), which may explain some of the 
variations in responses to Leptin. Studies on the ovarian cancer lines OVCAR-3 and 
A2780 have also shown that Leptin is involved in the activation of the estrogen 
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receptor pathway thereby indirectly promoting tumor cell growth (Choi et al., 2011). 
However, these studies are yet to be confirmed in vivo. 
1.5.4 OSM/OSMR and LIF/LIFR 
Oncostatin M (OSM) and Leukemia Inhibitory Factor (LIF) share many 
biological properties (Gomez-Lechon, 1999) due to the fact that they share receptor 
subunits, including the GP130 signal transducing subunit (Gearing et al., 1992). 
Upon binding of either ligand, the receptor complex activates similar signaling 
cascades, especially JAK2/STAT3 (Stahl et al., 1994, Stahl et al., 1995). LIFRα has 
been identified on a wide range of hematopoietic cells and cell lines originating from 
bone marrow, thymus, spleen, liver, placental tissue, and peritoneum (Hilton et al., 
1988). OSMRα is also expressed on many cell types, including endothelial cells, 
hepatic cells, lung cells and bone marrow (Gomez-Lechon, 1999).  
Both LIFR and OSMR have been shown to be frequently expressed in 
tumors, where they can activate downstream signaling pathways upon ligand 
stimulation (Savarese et al., 2002). OSM was shown to suppress the growth of some 
but not all breast and lung carcinoma cell lines (Douglas et al., 1997, Ganapathi et 
al., 1996), but to increase proliferation in prostate carcinoma cell lines (Mori et al., 
1999). The functional significance of LIFR in human solid tumor cell lines is also not 
fully understood. LIF and LIFR has been found to be expressed in breast, kidney and 
prostate cancer cell lines, and demonstrated to induce tumor growth in these cell 
lines either in an autocrine or paracrine manner (Dhingra et al., 1998, Kellokumpu-
Lehtinen et al., 1996). Autocrine activation of LIFR signaling has also been shown in 
ovarian cancer. However, this did not alter cell growth, but did cause a modest 
increase in the rate of apoptosis in these cells (Savarese et al., 2002).  
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1.6 JAK/STAT/SOCS pathway 
Cytokine receptors mediate several of their effects via activation of 
JAK/STAT proteins, particularly JAK2 and STAT3 in the core of the IL-6R family 
(Shimoda et al., 1997, Ward et al., 1999b, Dror et al., 2000, de Koning et al., 2000, 
Ilaria et al., 1999).  
1.6.1 JAK2/STAT3 in cancer 
Constitutive activation of both JAK2 and STAT3 has been reported in several 
disease states, including cancer. Thus, activating mutations in JAK2 contribute to 
various myeloproliferative disorders (Staerk et al., 2007), while increased activity 
contributes to both renal cell carcinoma (Wu et al., 2007) and lung cancer (Gao et al., 
2007). Much more is known about the STAT3 (Bromberg, 2002), which has been 
shown to play a key role in a variety of malignancies, including lung (Gao et al., 
2007) and breast (Sansone et al., 2007) cancers, with constitutively-activated mutant 
forms of STAT3 sufficient to transform fibroblasts in vitro (Bromberg et al., 1999). 
Though it’s a transcription factor functions, STAT3 can directly influence gene 
expression via specific binding sites in the promoters of responsive genes 
(Bromberg, 2001). Indeed, STAT3 ‘gene signatures’ have been elucidated (Alvarez 
et al., 2005). Many of the genes known to be regulated by STAT3 function in the 
broad categories of proliferation (eg. c-myc (Grivennikov and Karin, 2008) and 
Cyclin D1 (Leslie et al., 2006)), adhesion (eg. ICAM-1 (Yang et al., 2005b), 
GlyCAM-1 (Hou et al., 2003), E-cadherin (Sultan et al., 2005) and integrins 
(Panopoulos et al., 2002)) and survival (eg. HIF (Sansone et al., 2007)). Furthermore, 
STAT3 is also known to contribute to migration/invasion (Silver et al., 2004, 
Poehlmann et al., 2005). The activation of the JAK2/STAT3 pathway is augmented 
in some cancer is the epigenetic silencing of the negative regulator, SOCS3 (Isomoto 
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et al., 2007). Current understanding of the JAK2/STAT3 pathway in ovarian cancer 
is limited however, although one report has described a positive correlation between 
STAT3 activation and proliferation (Rosen et al., 2006). 
The discovery of constitutively active STAT3 in head and neck cancer and 
multiple myeloma, provided the link between STAT3 activity and its transformation 
capabilities in vivo (Song and Grandis, 2000). High STAT3 activity has subsequently 
been detected in leukaemias, lymphomas, breast cancer, melanoma, ovarian cancer, 
lung cancer, cervix cancer, pancreatic cancer, and prostate cancer (Sandur et al., 
2006). Some of these studies have directly demonstrated the contribution of STAT3 
in oncogenesis (Yu and Jove, 2004, Turkson et al., 1998, Bromberg et al., 1998). 
Definitive evidence for a causative role of STAT3 in cancer was provided following 
the development of a constitutively active form of STAT3 (STAT3C), which was 
found to be sufficient for malignant transformation (Liddle et al., 2006).  
 STAT3 has been identified as playing a key role in cancer progression with 
inappropriate activation of kinases, in particular tyrosine kinases often via aberrant 
cytokine or growth factor receptor signaling which leads to the persistent activation 
of STAT3 in numerous forms of cancer (Gibbs, 2000). STAT3 activity has been 
shown to play a critical role in tumor cell growth, angiogenesis, resistance apoptosis, 
and evasion of the host’s immune surveillance (Yu and Jove, 2004). The 
involvement of STAT3 in these critical processes has made it a popular target for 
anti-cancer drugs (Yu and Jove, 2004, Lewis et al., 2008, Frank, 2007). Inhibition of 
STAT3 by a variety of means has been shown to exert anti-cancer effects (Frank, 
2007). 
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1.7 Hypothesis and Aims  
This Project is based on the Hypothesis that aberrant activation of the 
JAK2/STAT3 pathway via IL-6R family members contributes to the malignant 
phenotypes of ovarian cancer, which may provide new therapeutic opportunities for 
this disease.  
This hypothesis was investigated by pursuing the following aims:  
(i) To evaluate the expression/activation of IL-6R family signaling components in 
normal and neoplastic ovarian specimens. 
(ii) To investigate the functional role of specific IL-6R family members in mediating 
key ovarian cancer phenotypes. 
(iii) To understand the importance of the JAK2/STAT3 in mediating the effects of 
these receptors. 
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2. Materials & Methods 
2.1 Materials 
The following companies supplied reagents and equipment used in this work: 
Abcam, Cambridge, MA, USA 
Agilent Technologies, Forest Hill, Victoria, Australia 
Ajax Chemicals, Sydney, NSW, Australia 
Ambion, Austin, TX, USA 
American Type Tissue Culture, Cryosite, NSW, Australia 
Amersham Biosciences, Piscataway, NJ, USA 
Amresco, Solo, OH, USA 
Applied Biosystems, Foster City, CA, USA 
Astral Scientific, Gymea, NSW, Australia 
Australian Science Supply, Glen Waverley, Victoria, Australia 
Axygen Scientific, Union City, CA, USA 
Barwon Health Pharmacy Services, Geelong, Victoria, Australia 
BD Biosciences, North Ryde, NSW, Australia 
Becton Dickinson Labware, Franklin Lakes, NJ, USA 
Berthold Technologies, Bundoora, Victoria, Australia 
BioBest, Wentworthville, NSW, Australia 
BioCore Pty. Ltd, Alexandria, NSW, Australia 
Biocorp, Quebec, Montreal, Canada 
Bioline, Alexandria, NSW, Australia 
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Bio-Rad, Regents Park, NSW, Australia 
Cell Signaling Technologies Inc., Danvers, MA, USA 
Dako LSAB, Cambellfield, Victoria, Australia 
Eppendorf, Hamburg, Germany 
Fluka BioChemika, Castle Hill, NSW, Australia 
Gilson, Guelph, ON, Canada 
Greiner Bio-one GmbH, Frickenhausen, Germany 
Hospira, Melbourne, Victoria, Australia 
Integrated Sciences, Willoughby, NSW, Australia 
Interpath, West Heidelberg, Victoria, Australia 
Invitrogen, Mount Waverley, Victoria, Australia 
Leica Microsystems GmbH, Wetzlar, Germany 
Life Research Pty. Ltd., Scoresby, Victoria, Australia 
Life Technologies, Rockville, MD, USA 
MatTek Corporation, MA, USA 
Merck Millipore, Kilsyth, Victoria, Australia 
Merck/Calbiochem, San Diego, CA, USA 
Millennium Science Pty. Ltd., Mulgrave, Victoria, Australia 
Millipore, Billerica, MA, USA 
Nalgen Nunc International, Roskilde, MA, USA 
Olympus, Tokyo, Japan 
Pacific Lab Products, Blackburn, Victoria, Australia 
Perkin Elmer, Glen Waverly, Victoria, Australia 
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Pfizer, Perth, Australia 
Promega, Annandale, NSW, Australia 
Proscience, Nunawading, Victoria, Australia 
RnDSystems, Minneapolis, MN, USA 
Sigma-Aldrich, Castle Hill, NSW, Australia 
Stratagene GmbH, Heidelberg, Germany 
Thermo Fisher, Scoresby, Victoria, Australia 
Thermoline Scientific, Smithfield, NSW, Australia 
Victorian Bio Bank, Melbourne, Victoria, Australia 
Whatman, Middlesex, United Kingdom 
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2.1.1 Oligonucleotides  
Standard oligonucleotides used for reverse transcription-polymerase chain 
reaction (RT-PCR), quantitative real time-polymerase chain reaction (qRT-PCR) and 
sequencing were designed using the NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and Primer3 
(http://frodo.wi.mit.edu/primer3/) design tools and synthesized by Sigma-Aldrich 
(Table 2.1.) 
Table 2.1: List of oligonucleotides used in this study 
Primer Name Ref No Sequence 
Size 
(bp) 
hu  B-ACTIN fd AW888 GGACTTCGAGCAAGAGATGG 
230 
hu  B-ACTIN rv AW889 AGCACTGTGTTGGCGTACAG 
hu BCL2 fd AW872 GGATGCCTTTGTGGAACTGT 
236 
hu BCL2  rv AW873 AGCCTGCAGCTTTGTTTCAT 
hu c-MYC fd AW860 TACCCTCTAACGACAGCAG 
478 
hu c-MYC rv AW861 TCTTGACATTCTCCTCGGTG 
hu CNTF fd AW804 CAGGGCCTGAACAAGAACAT 
195 
hu CNTF rv AW784 ATGGAAGTCACCTTCGGTTG 
hu CNTFR fd AW783 GGACATTGATGTGCTTGGTG 
175 
hu CNTFR rv AW799 ATGGCAGTGTCACGTCAGAG 
hu CRP fd AW1068 ATACCCAGGCCACAAGAGTG 
204 
hu CRP rv AW1069 ACGTCCTCTCAGCTTGGAAA 
hu CYCLIND1 
fd 
AW1081 CCTAAGTTCGGTTCCGATGA 
154 
hu CYCLIND1 
rv 
AW1082 ACGTCAGCCTCCACACTCTT 
hu E-CAD fd AW1085 TGCCCAGAAAATGAAAAAGG 
200 
hu E-CAD rv AW1086 GTGTATGTGGCAATGCGTTC 
hu EGF fd AW852 TCTCAACACATGCTAGTGGCTGAAATCATGG 
527 
hu EGF rv AW853 TCAATATACATGCACACACCATCATGGAGGC 
hu EGFR fd AW854 CAGCGCTACCTTGTCATTCA 
195 
hu EGFR rv AW855 TGCACTCAGAGAGCTCAGGA 
hu GAPDH fd AW892 ATGTTCGTCATGGGTGTGAA 
246 
hu GAPDH rv AW893 GTCTTCTGGGTGGCAGTGAT 
hu G-CSF fd AW790 CAGAGCTTCCTGGAGGTGTC 
229 
hu G-CSF rv AW789 ATGGGAGGACAGGAGCTTTT 
hu G-CSFR fd AW792 CCTGGAGCTGAGAACTACCG 
236 
hu G-CSFR rv AW793 CTTCTGAAGGCAGGTGGAG 
hu GP130 fd AW795 CCCTCAGTACCTGGACCAAA 246 
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hu GP130 rv AW797 TGTAGATGGCGCTGATGGTA 
hu IB6 fd AW1091 CTCTTTCCAGTGTGGGGTGT 
199 
hu  IB6 rv AW1092 CTGGCAATAAGGCCCATAAA 
hu ICAM1 fd AW1083 GGCTGGAGCTGTTTGAGAAC 
202 
hu ICAM1 rv AW1084 ACTGTGGGGTTCAACCTCTG 
hu IL11 fd AW1062 GAGGGCGATTTGTCTGAGAG 
195 
hu IL11 rv AW1063 ACAAAAGGCCCTATGCAGTG 
hu IL11R fd AW1064 TTTCTTTCCTGGGACTGGTG 
154 
hu IL11R rv AW1065 TGGGTCCTCTACAGGTTTGG 
hu IL27 fd AW1021 GAGCAGCTCCCTGATGTTTC 
158 
hu IL27 rv AW1022 AGCTGCATCCTCTCCATGTT 
hu IL27R fd AW1027 GCCTTCTGCTCCAAAAGATG 
175 
hu IL27R rv AW1032 GGAGCAGCAGCAGGTAATTC 
hu IL31 fd AW1026 TTTCTGTGCCAACAGACACC 
195 
hu IL31 rv AW1031 CCACACTTAGCTGTCGGTCA 
hu IL31R fd AW1023 TCACAGATGAAGCCAGAACG 
169 
hu IL31R rv AW1028 GGCATCCTCGAACGTAGGTA 
hu IL6 fd AW786 TACCCCCAGGAGAAGATTCC 
175 
hu IL6 rv AW800 TTTTCTGCCAGTGCCTCTTT 
hu IL6R fd AW788 CTCCTGCCAGTTAGCAGTCC 
198 
hu IL6R rv AW787 TCTTGCCAGGTGACACTGAG 
hu LEPTIN fd AW794 GAAGACCACATCCACACACG 
189 
hu LEPTIN rv AW798 AGCTCAGCCAGACCCATCTA 
hu OBR fd AW796 GTGAAGCCTGATCCACCATT 
214 
hu OBR rv AW791 CCTCATACGAAGACCCAGGA 
hu OBR rv 
(universal) 
AW1121 ATAGCTTTTTCATTCTTTGGTGTG 78 
hu OBR rv       
(L isoform) 
AW1130 CTGATCAGCGTGGCGTATTT 439 
hu OBR rv      
(S1 isoform) 
AW1118 CTGTGGCCTTCCGCAGTG 227 
hu OBR rv      
(S2 isoform) 
AW1119 ACCTCCACCCAGTAGTTCCTT 176 
hu OBR rv      
(S3 isoform) 
AW1120 AGTTGGCACATTGGGTTCAT 200 
hu LIF fd AW803 CCCTGGTCCCTACTCAACAA 
234 
hu LIF rv AW802 CTGGACCCTGACACCCTAAA 
hu LIFR fd AW785 TGACTGCATTGCACAGATGA 
250 
hu LIFR rv AW801 ATCAGTACCACGGCCTGTTC 
hu MMP2 fd AW1089 ATGACAGCTGCACCACTGAG 
174 
hu MMP2 rv AW1090 ATTTGTTGCCCAGGAAAGTG 
hu MMP3 fd AW858 ATTCCATGGAGCCAGGCTTTC 
138 
hu MMP3 rv AW859 CATTTGGGTCAAACTCCAACTGTG 
hu MMP9 fd AW1093 TTGACAGCGACAAGAAGTGG 
179 
hu MMP9 rv AW1094 GCCATTCACGTCGTCCTTAT 
hu N-CAD fd AW1087 GACAATGCCCCTCAAGTGTT 179 
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hu N-CAD rv AW1088 CCATTAAGCCGAGTGATGGT 
hu OSM fd AW1024 CATCGAGGACTTGGAGAAGC 
228 
hu OSM rv AW1029 ACTGAGTGCATGAAGCGATG 
hu OSMR fd AW1025 CGCGTCAGAGTTTGCACTTA 
200 
hu OSMR rv AW1030 GTGTGTGGCACATTCCAAAG 
 
2.1.2 Antibodies, cytokines, growth factors and inhibitors 
For Western blotting, the following primary antibodies were used: rabbit anti-
phospho STAT3 (pTyr 705) (cat #  9131), rabbit anti-total STAT3 (cat # 9130), 
rabbit anti-E-Cadherin, rabbit anti-N-Cadherin, rabbit anti-Vimentin, rabbit anti-
Slug, rabbit anti-Snail (cat # 9782), rabbit anti-BCL2 ( cat # 2872), rabbit anti-
pNFκB p65 (pSer 536) (cat # 3039) , rabbit anti-NFκB p65 (cat #  6956), rabbit anti-
pERK (pTyr 204) (cat # 4373), rabbit anti-total-ERK (cat # 4372), rabbit anti-
phospho AKT (pSer 473) (cat # 4058) , rabbit anti-total-AKT (cat # 4057), rabbit 
anti-ERCC1 (Cell Signaling) ( cat # 3885), rabbit anti-CRP (cat # ab13426), rabbit 
anti-MDR1 (cat # ab170904), and rabbit anti-GST-pi (Abcam) (cat # ab135535) at a 
dilution of 1:1000 as well as mouse anti-Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) (Millipore) (cat #  CB1001) at 1:10000 dilution. 
Secondary antibodies for Western blot were: IRDye 800CW goat anti-mouse IgG 
(LiCor) and IRDye 680 goat anti-rabbit IgG (LiCor) as appropriate at 1:10000. For 
flow cytometry mouse anti-G-CSFR conjugated with PE or  rabbit anti-OBR 
(Abcam) followed by anti-rabbit Alexa Fluoro conjugated with FITC (Invitrogen) 
was used. For immunohistochemistry, mouse anti-G-CSFR (AbCam) or rabbit anti-
OBR (Abcam) or rabbit anti-phospho STAT3 (pTyr 705) or rabbit anti-total STAT3 
and developed using appropriate secondary antibodies and the Peroxidase Universal 
Kit (Dako) after elimination of non-specific peroxidase activity. 
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The following recombinant human cytokines and growth factors were used at 
10 ng/ml final concentration: Epidermal Growth Factor, Interleukin 6, Granulocyte 
Colony-Stimulating Factor (Cell Signaling) and Leptin (Sigma Aldrich). 
Where appropriate the following specific inhibitors were used: AG490 (Saito 
et al., 2006) (JAK inhibitor, Sigma Aldrich), WP1066 (Verstovsek et al., 2008) 
(JAK2 inhibitor, Bio Core), LLL12 (Lin et al., 2010a) (STAT3 inhibitor, Bio Core). 
2.1.3 Media and serum 
The following media were used to propagate cell lines: Dulbecco's Modified 
Eagle Medium (DMEM) (Invitrogen), McCoy’s 5a (Invitrogen), RPMI-1640 
(Invitrogen), Eagle’s Minimum Essential Medium (BME) (Invitrogen), Medium 199 
(Invitrogen), MCDB 105 (Sigma). These were supplemented with Fetal Bovine 
Serum (FBS) (Thermofisher), 2 mM L-Glutamine (Invitrogen), and 1%  Pen/Strep 
(Invitrogen). 
2.1.4 Cell lines  
The cell lines used in this study along with their respective media 
requirements are described in Table 2.2. 
Table 2.2: Cell lines used in this study 
Cell Line Description Source Media Reference 
CAOV3 
Ovarian 
adenocarcinoma 
ATCC cat no #HTB-
75 
DMEM+10% 
FBS 
(Karlan et al., 
1994) 
ES-2 
Ovarian clear cell 
carcinoma 
ATCC cat no #CRL-
1978 
McCoy’s 5a 
+10% FBS 
(Lau et al., 1991) 
HEY 
Ovarian 
adenocarcinoma 
Gift from N. 
Ahmed, Royal’s 
Women Hospital 
Melbourne 
DMEM+10%FBS 
(Shield et al., 
2007) 
NIH: 
OVCAR3 
Ovarian 
epithelial 
adenocarcinoma 
ATCC cat no #HTB-
161 
RPMI-1640 + 
20% FBS 
(Hamilton et al., 
1983) 
OV90 
Ovarian serous 
adenocarcinoma 
ATCC cat no #CRL-
11732 
1:1 mixture of 
MCDB 105 
medium/ Medium 
(Ahmed et al., 
2002, Lounis et 
al., 1998) 
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199 +15% FBS 
OVCA429 
Ovarian 
adenocarcinoma 
Gift from  N. 
Ahmed, Royal’s 
Women Hospital 
Melbourne 
 
1:1 mixture of 
MCDB 105 / 
Medium 199 
+10% FBS 
(Ahmed et al., 
2002) 
OVCA433 
Ovarian 
adenocarcinoma 
Gift from  N. 
Ahmed, Royal’s 
Women Hospital 
Melbourne 
1:1 mixture of 
MCDB 105 / 
Medium 
199+10% FBS 
(Ahmed et al., 
2002) 
 
 
 
OVCAR5 
Ovarian 
adenocarcinoma 
Gift from  N. 
Ahmed, Royal’s 
Women Hospital 
Melbourne 
RPMI+10% FBS 
(Buczek-Thomas 
et al., 1998) 
PA1 
Ovarian 
teratocarcinoma 
from ascites 
ATCC cat no #CRL-
1572 
BME+10% FBS 
(Provencher et 
al., 2000, Zeuthen 
et al., 1980) 
SKOV3 
Ovarian 
adenocarcinoma 
from ascites 
ATCC cat no #HTB-
77 
McCoy’s 5a + 
10% FBS 
(Fogh et al., 
1977) 
TOV 21G 
Ovarian 
adenocarcinoma 
ATCC cat no #CRL-
11730 
1:1 mixture of 
MCDB 105 
medium/ Medium 
199 + 15% FBS 
(Provencher et 
al., 2000) 
 
2.1.5 Chemotherapeutic agents 
Cells were treated with Paclitaxel (Hospira) (1 µg/ml for 5 days) or Cisplatin 
(Pfizer) (5 µg/ml for 5 days) for cytokine expression studies or at 12.5 µg/ml in 
combination with cytokines to induce apoptosis. 
2.1.6 Clinical Samples 
Ovarian epithelial tumours of different pathological grades were collected 
from patients diagnosed with high-grade ovarian carcinoma, after obtaining written 
informed consent under protocols approved by the Human Research and Ethics 
Committee (HREC #09/09) of The Royal Women’s Hospital, Melbourne, Australia, 
or via the Victorian Cancer Biobank and approved by the Deakin University Human 
Research Ethics Committee (DUHREC#2010-104).  The histopathological diagnosis 
and tumour grades were determined by staff pathologists as part of the clinical 
diagnosis.  Normal ovaries, needed for control comparisons were obtained from 
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patients undergoing surgery as a result of suspicious ultrasound images or a family 
history of ovarian cancer.  Specimens were snap frozen under liquid nitrogen and 
subsequently stored at -80°C for expression analysis or preserved in Tissue-TekR 
embedding medium and frozen for immunohistochemical studies. 
2.2 Cell methods 
2.2.1 Cell line maintenance 
Cells were retrieved from liquid nitrogen and slowly thawed in approximately 
1 ml of the relevant medium (Table 2.2). The cells were then centrifuged at 100 g for 
5 min, the supernatant removed and the cell pellet resuspended in fresh medium. 
Cells were then transferred to a culture flask, which was maintained at 37°C and 5% 
(v/v) CO2 in an air-jacketed CO2 incubator.  
2.2.2 Subculturing 
Cells were sub-cultured to about 80% confluence. The culture medium was 
removed and the cells were washed twice with Phosphate-Buffered Saline-EDTA 
(1×) (Ameresco) before trypsinization. The cells were trypsinized with 0.25% (1×) 
Trypsin–EDTA (Invitrogen) for 3-5 min at 37°C. Once cells were detached fresh 
medium was added to wash the cells, which were centrifuged at 100 g for 5 min. The 
cell pellet was resuspended in fresh medium, cells were counted using a 
hemocytometer and a fixed number of cells were seeded into an appropriate flask or 
plate. 
2.2.3 Cell cryopreservation 
Prior to cryopreservation a single cell suspension was prepared using Trypsin 
as described in Section 2.2.2, and then transferred to cryovials, which were 
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centrifuged at 100 g for 5 min. The supernatant was removed and approximately 300 
µl of freezing mixture (containing relevant media and DMSO in the ratio 9:1) was 
used to gently resuspend the pellet. Cryovials were sealed and stored in a Mister 
Frosty
™
 (Thermo Scientific) overnight at -80
o
C, before being transferred to liquid 
Nitrogen for longer term storage. 
2.2.4 Fluorescent labeling of cells 
Cells were labeled with either CM-Dil (red fluorescence) or DiO (green 
fluorescence) (Vybrant, Invitrogen) as described (Pruvot et al., 2011). Confluent 
cells were trypsinized, washed with 67% (v/v) Dulbecco's Phosphate-Buffered Saline 
(GIBCO, Invitrogen), transferred to 1.5 ml Eppendorf tubes and centrifuged 5 min at 
100 g. The cell pellet was re-suspended in DPBS containing either CM-Dil (4 ng/μl 
final concentration) or DiO (200 μM final concentration). Cells stained with CM-Dil 
were incubated for 4 min at 37°C and then 15 min at 4°C. Cells stained with DiO 
were incubated for 20 min at 37°C. Following incubation, cells were centrifuged for 
5 min at 100 g and the cell pellet re-suspended in 100% (v/v) Fetal Bovine Serum, 
centrifuged again and washed twice with DPBS prior to injection. 
2.2.5 Migration assay 
Confluent cells in a 6-well plate were serum starved for 24 h prior to 
wounding of the monolayer with a sterile 200 µl pipette tip. Where required, 
appropriate growth factors, cytokines and/or inhibitors were added 1 h prior to 
wounding. Three representative fields were marked and imaged immediately after 
and 15 h after wounding as described (Lim et al., 2007, Chan et al., 2008). Cell 
migration across the wound was analyzed using Cell Profiler® software from Broad 
Institute (Carpenter et al., 2006). 
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2.2.6 Chemotaxis assay 
Chemotaxis assays were performed with a two-chamber transwell (Corning) 
as described previously (Zhao et al., 2011), using a polycarbonate filter insert with 3 
μm pores. Cells were trypsinized and suspended in serum-free medium containing 
0.1% (v/v) FBS at a concentration of 1×10
5
 cells/ insert. The cells were placed in the 
upper chamber and media was placed in the lower chamber. After 4 h at 37°C, the 
cells in the upper chamber were wiped off with a cotton swab. The cells on the lower 
surface of the filter were fixed with 4% (v/v) Paraformaldehyde for 1 min at room 
temperature, permeabilized with 100% methanol, washed with PBS and stained with 
Giemsa solution. Migration was quantitated by selecting ten random fields and 
counting the number of migrated cells. 
2.2.7 Growth assay 
Growth rates were assessed by manual cell counting as described (Ouellet et 
al., 2008) . On day 0, 1×10
5
 cells were seeded onto 60 mm petri dishes. On day 1, 2, 
3, 4, cells were trypsinized, resuspended in medium and counted using a 
hemocytometer. Each experiment was performed in triplicate for each harvest and 
repeated thrice.  
2.2.8 Apoptosis assay 
Cells were grown to confluence and treated with 0.1% Sodium Azide (Huang 
et al., 2008) or cisplatin (12.5 µM) or paclitaxel (1 µM) (Das et al., 2003) to induce 
apoptosis and in combination with appropriate growth factors, cytokines and/or 
inhibitors, before analysis using FITC Annexin V Apoptosis Detection Kit I (BD 
Phamingen
TM), according to the manufacturer’s instructions (van Engeland et al., 
1996). 
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2.2.9 Viability assay 
Cells were treated with appropriate growth factors, cytokines and/or 
inhibitors, and the viability was determined using a Trypan Blue cell exclusion assay 
(GIBCO, Invitrogen) and manual counting using a hemocytometer, as described 
(Dugas et al., 2010).  
2.3 DNA/RNA methods 
2.3.1 Isolation of total RNA  
Approximately 2×10
6
 were harvested in 1 ml Trizol reagent (Invitrogen), and 
the phases separated by the addition of 200 μl chloroform. After a brief incubation at 
room temperature, the Trizol-chloroform mix was centrifuged at 12000 g for 10 min 
at 4°C. RNA was precipitated with the addition of 500 μl isopropanol and incubated 
at room temperature (RT) for 10 min, followed by centrifugation at 12000 g for 10 
min at 4°C. The RNA pellet was washed with 75% (v/v) ethanol and centrifuged at 
7500 g for 10 min at 4°C. RNA was subsequently resuspended in (20-50 μl) sterile 
nuclease-free water (Ambion). 
2.3.2 Nucleic acid concentration and purity 
DNA/RNA concentration and purity were determined by UV 
spectrophotometry at 260 nm and 280 nm wavelengths using a NanoVue™ (General 
Electric) following the manufacturer’s instructions. RNA was considered pure with 
an A260/A280 ratio of >1.8, and DNA with an A260/280 ratio of >1.6. 
2.3.3 cDNA synthesis 
cDNA was synthesized from 0.5 µg of total RNA using an iScript cDNA 
Synthesis Kit (BioRad), following the manufacturer’s recommendations. Negative 
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controls were prepared by substituting iScript reverse-transcriptase enzyme mixture 
with an equivalent volume of water (no RT-control). 
2.3.4 Polymerase chain reaction (RT-PCR)  
PCR reactions were performed on a My-Cycler thermal cycler (Bio-Rad) 
using 25 μL reaction volumes containing 500 ng cDNA template, 5.5 μL sterile 
nuclease free water (Ambion), 12.5 μL PCR GoTaq Green Master Mix containing 
Taq DNA polymerase, dNTPs, MgCl2 and reaction buffers at optimal concentrations 
(Promega) and 10 μM each of gene specific forward and reverse primer (Table 2.1). 
Amplification conditions were typically 94°C for 2 min, followed by 94°C for 1 min, 
58°C for 1.5 min and 72°C for 1 min for a total of 30 cycles, with a final incubation 
of 72°C for 10 min, unless otherwise specified. Control reactions were performed 
using the no RT-control to confirm the absence of contaminating genomic DNA, and 
without template to ensure that amplicon products were not the result of 
contamination or primer-dimer effects. Parallel amplification of the β-ACTIN 
(ACTNB) gene was used as a loading control.  
2.3.5 Agarose gel electrophoresis 
Electrophoretic analysis of DNA was performed using 1-3% (w/v) agarose 
(Amresco) gels in 1×TAE buffer (4.8% (w/v) Tris-HCl, 1.1% (v/v) Glacial acetic 
acid, 3.7% (w/v) 0.5 M EDTA; pH8.0) with the addition of  SYBR® Safe (1:10000) 
(Invitrogen) per 50 ml. Electrophoresis was undertaken at 110 V for 30-60 min in a 
Bio-Rad mini-tank apparatus, followed by imaging under ultra violet (UV) 
illumination using a Chemidoc XRS Molecular Imager System (Bio-Rad) using 
Quantity One software (Bio-Rad). 
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2.3.6 Quantitative real time polymerase chain reaction (qRT-PCR)  
Gene expression was quantified by qRT-PCR on the Agilent Strategene 
MX3000P. Reactions (25 μL) contained 3.125 μL nuclease-free water, 3.125 μL 
cDNA template (1:5 dilution), 12.5 μL iQ SYBR Green Supermix containing 
Reaction buffer, dNTPs, 50 U/ml iTaq DNA polymerase, 6 mM MgCl2, 20 nM 
SYBR
®
 Green I (Bio-Rad) and 3.125 μL each of forward and reverse primer (2.4 
μM) (Table 2.1). Typical PCR conditions consisted of 95°C for 30 sec, followed by 
45 cycles of 95°C for 10 sec, 60°C for 30 sec, 72°C for 20 sec, then 95°C for 1 min, 
55°C for 1 min, and finally incremental increases (0.5°C) from 55°C to 95°C to 
establish the melting curve for each sample. Appropriate control reactions were 
performed to ensure products were not the result of DNA contamination or due to 
primer-dimer formation. Data retrieved from these assays were analysed using the 
Livak method (Livak and Schmittgen, 2001).  
2.4 Protein methods 
2.4.1 Immunohistochemistry 
Paraffin embedded primary tumor samples were analyzed by 
immunohistochemistry, as previously described (Colomiere et al., 2009, McCulloch 
et al., 2009). Briefly, tissue sections were blocked (1:50 human serum) and incubated 
with  primary antibodies, washed and developed using appropriate secondary 
antibodies and the Peroxidase Universal Kit (Dako) after elimination of non-specific 
peroxidase activity. Slides were counterstained with 1% (w/v) hematoxylin to 
highlight cell nuclei. Optical image capture and analysis was performed using 
AxioVision and K5400 Zeiss software image analysis on a Zeiss Axioskop2 
Microscope. Ten fields from each section were analysed in a “blind” fashion and the 
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percent tissue staining determined, which was arbitrarily scored as follows: 0 
(≤10%), 1 (≥11-25%), 2 (≥26-50%), 3 (≥51-75%), 4(≥76-90%) and 5 (≥91-100%). 
Control slides were processed in the absence of primary antibody, secondary 
antibody and chromogenic substrate, or with isotype control IgG to ensure 
specificity. 
2.4.2 Protein isolation 
Approximately 2×10
6
 cells were harvested using a cell scraper and suspended 
in 0.5 ml of RIPA Lysis Buffer, containing 20 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% (v/v) NP-40, 1% sodium deoxycholate, 
2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1 µg/ml 
leupeptin (Sigma) and phosphatase inhibitor cocktail (5mg/ml). After 5 min on ice, 
cells were centrifuged at 14,000 g for 15 min at 4°C, with the supernatant containing 
extracted proteins collected and stored at -80°C. 
2.4.3 Protein concentration determination 
Total protein content was determined using a BCA Protein Determination Kit 
(Pierce) following the manufacturer’s instructions, using bovine serum albumin as 
the standard and reading the absorbance at a wavelength of 562 nm using a 
PerkinElmer VICTOR X Multilabel Plate Reader. 
2.4.4 Western blotting 
Protein lysates were denatured by heating at 100
o
C for about 3 min and 
cooling immediately on ice for 5 min before separation on a 10% Tris-HCl 
Polyacrylamide gel (1.5 ml 1.5 M Tris Buffer, 2.5 ml 30% (v/v) acrylamide mix, 
3.475 ml water, µl 10% (v/v) APS and 15 µl TEMED), and electroblotted to a 
polyvinylidene difluoride (PVDF) membrane in 20%  (v/v) methanol, 25 mM Tris 
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base, 192 mM glycine, pH 8.0. The PVDF membranes were blocked with 5% (w/v) 
BSA in 20 mM Tris base, pH 7.6, containing 200 mM NaCl, and 0.05% (v/v) 
Tween-20, and then incubated with primary antibodies at 1 μg/ml overnight at 4oC. 
Membranes were then washed and incubated with a secondary antibody IRDye 
800CW Goat anti-Mouse IgG and IRDye 680 Goat anti-Rabbit IgG (1 μg/ml) (LI-
COR Biosciences) and antibody binding detected using an Odyssey Imager. 
2.4.5 Flow cytometry  
Cell lines were grown to confluence prior to harvest for fluorescence 
activated cell sorter (FACS) analysis. Cell monolayers were washed twice with 
phosphate buffered saline (PBS), detached with 0.25% (w/v) trypsin-EDTA solution, 
collected by centrifugation and washed a further two times with PBS.  
Approximately 1×10
6
 cells were fixed using 4% (w/v) PFA and subsequently 
blocked for 30 min in PBS containing 10% (v/v) goat serum. After incubation, the 
cells were washed twice with PBS, incubated with appropriate antibody at a 
concentration of 1 µg/µl for 1 h at room temperature, followed by three washes in 
PBS. The cells were then incubated with appropriate secondary antibody for 30 min 
at room temperature. The sample were washed and resuspended with PBS and were 
analysed on FACS Canto (Becton Dickinson) using FACS DIVA software, in 
comparison to appropriate controls. 
2.4.6 Enzyme – Linked immunosorbent assay (ELISA) 
ELISA was performed using a Human G-CSF Quantikine ELISA Kit 
(RnDSystems, Minneapolis, USA), on conditioned media, following the 
manufacturer’s instruction (Robinson et al., 2009). The absorbance was read using a 
Fusion-Alpha-HT plate reader. 
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2.4.7 Electrophoretic mobility shift assay (EMSA) 
Cells treated with/without cytokines and inhibitors were washed with 1 ml 
cold PBS/0.1 mM Na3VO4 before resuspending in 200 μl hypotonic buffer (200 mM 
HEPES; pH 8, 1 mM Na3VO4, 20 mM NaF, 1 mM EDTA, 0.2 mM DTT, 1×protease 
inhibitor cocktail). Cells were lysed by the addition of 4 μl 10% (v/v) Tween-20 
followed by vortexing for 10 sec. Nuclei were pelleted by centrifugation at 13000 
rpm for 30 sec at 4°C and then resuspended in 20 μl hypertonic buffer (100 mM 
HEPES pH 8, 420 mM NaCl, 20% (v/v) glycerol, 1 mM Na3VO4, 20 mM NaF, 1 
mM EDTA, 1 mM DTT, 1×protease inhibitor cocktail) before rocking for 30 min at 
4°C to extract nuclear proteins. Samples were then centrifuged at 13000 rpm for 20 
min at 4°C and the supernatant transferred to a fresh tube for storage at –80°C. 
Nuclear extracts were thawed on ice and an aliquot incubated with 1 μg dI-dC 
(Sigma) and approximately 200 cpm 
32
P-labelled STAT (m67) probe in 1×Lamb 
binding buffer (10 mM HEPES; pH 7.6-7.8, 17 mM NaCl, 3 mM NaMoO4, 0.85 
mM DTT, 5% (v/v) glycerol, 0.15 mM MgCl2) at room temperature for 20-30 min. 
Samples were subsequently loaded onto a 4% (w/v) (29:1 acryl:bis-acryl) acrylamide 
½×TBE vertical gel and run at 80 V for 3 h before drying and being subjected to 
autoradiography as described (Ward et al., 1999a) 
2.5 Animal studies 
2.5.1 Zebrafish maintenance 
Wild-type zebrafish were commercially sourced and reared using standard 
practices (Kimmel et al., 1995) at the Deakin University Aquarium Facility. Water 
temperature was maintained at 28.5°C, pH 7.0. An automatic cycle of 14 h of light 
and 10 h of dark simulated the day/ night cycle. Adult zebrafish were fed daily with a 
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mixture of brine shrimp and flake food, with additional protein supplements for 
laying pairs. Embryos were collected after spawning and allowed to develop 
synchronously in egg water (2.5% (w/v) Na2HPO4; pH 6.0–6.3) within a Petri dish at 
28°C. 
2.5.2 Xenotransplantation  
Xenotransplantation into zebrafish embryos was performed essentially as 
described (Marques et al., 2009, Latifi et al., 2011). Fluorescently labelled cells were 
suspended in Daineau solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 
mM CaCl2, 5.0 mM HEPES; pH 9.0), and ~100 cells injected into the yolk sac of 2 
day post fertilization (dpf) dechorionated and anesthetized with 0.1 mg/ml of 
benzocaine as published (Liongue et al., 2009a). Embryos were incubated at 35°C, 
and xenotransplated cells visualized using a confocal microscope (Olympus 
FluoView 1000, Australia) at 24 and 48 hours post injection (hpi). 
2.6. Statistical Analyses 
All statistical analyses were performed using GraphPad Prism 4. Data were 
expressed as mean ± S.E.M. The statistical correlation of data between groups was 
analyzed by one-way analysis of variance (ANOVA) and a two-tailed Student’s t 
test, where p<0.05 was considered significant. 
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3.1 Introduction 
The etiology of ovarian cancer remains poorly understood, although it has 
been postulated that the repetitive breaking and repair of the ovarian surface 
epithelium in the course of the ovulation process has a tumor promoting influence 
(Auersperg et al., 2001). This repair process is governed by a variety of growth 
factors and cytokines acting in a paracrine and/or autocrine fashion (Kwintkiewicz 
and Giudice, 2009).  
The IL-6R family of cytokine receptors are members of the class I 
hematopoietin cytokine receptors. These consist of a ligand specific receptor chain, 
and often a separate, shared signal-transducing chain, such as GP130 (Kishimoto et 
al., 1995, Nakashima and Taga, 1998, Taga, 1997). The IL-6R family signals through 
various intracellular signaling cascades, including the JAK/STAT pathway, with 
JAK1/2 and STAT3 being preferentially utilized.  
A number of studies have implicated perturbation of the cytokine 
receptor/JAK/STAT pathway in a range of solid tumors by promoting tumor cell 
proliferation and survival, angiogenesis and immune evasion (O'Sullivan et al., 2007, 
You et al., 2012, Doucette et al., 2012, Sansone and Bromberg, 2012). Both tumor 
cells and immune cells are known to secrete cytokines and growth factors to enable 
both autocrine and paracrine signaling that underpins these key cancer phenotypes 
(Punnonen et al., 1998, Zeimet et al., 1998, Zebrowski et al., 1999).Therefore, the 
expression of functional IL-6 receptors on tumors cells suggests a potential role in 
tumorigenesis (Lu et al., 2006, Chalaris et al., 2011).  
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Studies have suggested a role for aberrant cytokine receptor signaling in 
ovarian cancer (Tsai-Turton et al., 2009). For example, several studies have shown 
autocrine activation of the IL-6 receptor mediates a number of malignant phenotypes 
in ovarian cancer cells (Colomiere et al., 2009, Guo et al., 2010). In light of this, the 
aim of this Chapter was to comprehensively evaluate the expression of members of 
the IL-6 receptor family and their ligands in ovarian cancer.  
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3.2 Results 
3.2.1 Expression of IL-6 family receptors and their ligands in ovarian cancer 
cell lines 
3.2.1.1 Basal level expression   
The expression of the genes encoding components of the IL-6R family and 
their respective ligands was determined using semi-quantitative PCR on a panel of 
ovarian cancer cell lines, with -ACTIN used as a control for input RNA. In addition, 
expression of EGF and EGFR was examined as EGF/EGFR signaling is a known 
mediator of ovarian cancer pathology. As previously described (Kohler et al., 1989, 
Kohler et al., 1992, Psyrri et al., 2005, Colomiere et al., 2009), EGFR was expressed 
in all cell lines examined, with lower expression of EGF.  
For the IL-6R family chains, the common signaling chain GP130 was almost 
universally expressed. Other individual chains were broadly expressed in unique 
patterns, which was irrespective of the ovarian cancer subtype. IL-6R, LIFR and 
OSMR were found to be widely expressed. Most of the cell lines also expressed IL-
11R, IL-27R and IL-31R although often at low levels, with the OVCAR3 cell 
line not expressing IL-27R, and both CAOV3 and OV90 not expressing IL-31R. 
G-CSFR, OBR and CNTFR were found to be expressed in a subset of cell lines. 
In terms of ligands, all cell lines expressed IL-6, LIF, CNTF and IL-11 to some 
extent. G-CSF, LEPTIN, OSM and IL-31 were variably expressed, while IL-27 was 
only expressed by a single cell line (Figure 3.1).  
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Figure 3.1: Basal expression of IL-6R family members and their ligands in 
ovarian cancer  
RNA derived from a panel of ovarian cancer cell lines was analyzed with primers 
specific for genes encoding components of IL-6R family members along with their 
ligands using semi-quantitative RT-PCR, as shown. The relative expression of each 
was scored on a 0-5 scale where 0 being no expression and 5 being high expression , 
as indicated in the key. 
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Based on the expression pattern of the individual receptor chains, it was 
possible to deduce which cell lines expressed particular receptor complexes. Most 
expressed IL-6R (IL-6R+GP130), LIFR (LIFR+GP130) and OSMR 
(OSMR+GP130), while many expressed IL-11R (IL-11R+GP130) and IL-31R 
(IL-31R+OSMR+GP130). However, IL-27R (IL-27R+IL-27R+GP130) and 
CNTFR (CNTFR+LIFR+GP130), along with the homodimeric G-CSFR and OBR, 
were expressed by just a subset of cell lines. The broad presence of these complexes 
and their ligands also suggested autocrine activation was possible for multiple 
receptors in each cell line.   
3.2.1.2 Expression following cytokine or growth factor stimulation  
Studies have previously demonstrated that stimulation with cytokines and 
growth factors could potentially impact on ligand/ receptor expression (Colomiere et 
al., 2009, Wang et al., 2008). Therefore, the various cell lines were also treated with 
IL-6 or EGF and reanalyzed for the expression pattern of the IL-6R family 
components and their ligands. In comparison to unstimulated cells, the overall 
expression patterns when stimulated with IL-6 or EGF did not markedly change, 
although the relative levels of individual gene expression did (Figure 3.2). A group 
of cell lines showed a generally decreased expression in response to IL-6 and EGF 
(ES2, OVCA433), others showed generally increased expression (CAOV3, SKOV3, 
OVCA429), and in others there was no effect with IL-6 but varied expression with 
EGF (OV90, HEY) or when IL-6 but not EGF caused increased expression (PA1).  
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Figure 3.2: Alteration in expression of IL-6R family members and their ligands 
in ovarian cancer by EGF and IL-6  
A panel of ovarian cancer cell lines was treated with either EGF (10 ng/ml) or IL-6 
(10 ng/ml) for 1h in comparison with untreated cells, and analysed for the expression 
of IL-6R family components and ligands as described in Figure 3.1.  
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3.2.2 Expression of selected IL-6R family members in ovarian cancer 
Having established broad expression of IL-6R family members in ovarian 
cancer cell lines, a sub-set of these receptors were analysed in patient samples. This 
included two archetypal receptors using a ligand-specific chain and GP130, IL-6R 
and LIFR, one heterotrimeric receptor, CNTFR, that is a complex of CNTFR 
LIFR and GP130, and two homomeric receptors, G-CSFR and OBR. This involved 
RT-PCR analysis of the transcripts encoding GP130, IL-6R, LIFR, CNTF, G-
CSFR, OBR, as well as those encoding their ligands: IL-6, LIF, CNTF, G-CSF and 
Leptin (Table 3.1). IL-6R, G-CSFR and CNTFR chains were not expressed in the 
benign mucinous cancer type, whereas the LIFR chain (1/4) and OBR chain (2/4) 
were expressed in a few samples of this type. In contrast, the benign serous type 
expressed IL-6R (3/4), LIFRand OBR (4/4), but not G-CSFR or CNTFR. 
There was, however, strong expression of all receptor chains in the Grade 3 serous 
cancer type. Importantly, the common signal transducing chain GP130 was 
universally expressed. These results suggests the presence of the following receptor 
complex: in benign mucinous type LIFR (1/4) and OBR (2/4); in benign serous type: 
IL-6R (3/4), LIFR (4/4), OBR (4/4); and in Grade 3 serous type: IL-6R, LIFR, OBR, 
CNTFR, G-CSFR.  
The expression of the respective ligands was found to be irrespective of 
cancer type. The strong co-expression of ligands and their receptor complexes in the 
Grade 3 serous type indicates a strong possibility of autocrine activation in these 
cells.  
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Table 3.1: Summary of the gene expression profile of selected IL-6R family 
components and their ligands in ovarian cancer samples. 
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Grades 
 
Genes 
Benign 
(Mucinous) 
Benign 
(Serous) 
Grade 3 
(Serous) 
IL-6R 0/4 3/4 3/4 
IL-6 0/4 3/4 4/4 
LIFR 1/4 4/4 4/4 
LIF 4/4 4/4 4/4 
G-CSFR 0/4 0/4 3/4 
G-CSF 4/4 4/4 4/4 
OBR 2/4 4/4 4/4 
Leptin 4/4 4/4 4/4 
CNTFR 0/4 0/4 3/4 
CNTF 4/4 4/4 4/4 
GP130 4/4 4/4 4/4 
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3.2.3 Expression of G-CSFR and OBR components in ovarian cancer 
The potential involvement of IL-6/IL-6R was not unexpected given other 
studies. However, the other results were intriguing. Of particular interest was the 
expression of G-CSFR on high grade tumors, since G-CSF is used to restore 
neutrophils after chemotherapy, and of OBR, given the correlation between Leptin 
levels in obese individuals and cancer incidence. Therefore, the focus of my research 
narrowed to analysing these two cytokine receptor complexes and their ligands, with 
IL-6/IL-6R serving as a positive control. The expression patterns of these 
ligands/receptor sets were analysed using Real-Time PCR on 17 Grade 3 serous 
patient samples (Figure 3.3A-C). The majority of samples showed statistically-
significant elevation in expression levels of both G-CSF/G-CSFR and Leptin/OBR 
compared to normal samples.  
In the case of G-CSFR, the availability of a suitable antibody meant that this 
study could be extended to primary tissue sections. Immunohistochemistry with -G-
CSFR confirmed the absence of G-CSFR expression on normal ovaries (Figure 3.4 
A), occasional weak staining on benign tumors (Figure 3.4B), but significant 
scattered epithelial staining within a cohort of tumors (Figure 3.4C), along with some 
vessel-associated staining. In total, ~60% (22/36) of tumor samples tested showed 
significant G-CSFR staining (score  2), compared with 0% (0/11) in normal 
controls and 20% (2/10) in benign tumors. Parallel staining with anti-pSTAT3 
revealed an overall low level epithelial staining on normal ovary and benign tumors 
(Figure 3.4D, E), but significant staining of vessels (Figure 3.4E). In contrast, a 
cohort of Grade 1-3 tumors again exhibited strong scattered pSTAT3 epithelial 
staining (Figure 3.4F). Importantly, the majority of samples with a significant G-
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CSFR staining score were also positive for pSTAT3 staining (Figure 3.4G, H), 
consistent with active signaling in these cells. 
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Figure 3.3: Expression of selected IL-6R components in primary ovarian cancer  
RNA derived from Grade 3 ovarian carcinoma samples was analyzed by qRT-PCR 
with primers specific for G-CSFR and G-CSF (A), IL-6R and IL-6 (B) and OBR and 
LEPTIN (C). These were normalized relative to -ACTIN, and compared to the 
expression observed in normal tissues . Tumor samples (shaded in dark blue) with 
statistically significant differences in expression and tumor samples (shaded in light 
blue) with non-statistically significant difference in expression compared to standard 
deviation of normal controls (red normal bar) are indicated (*p<0.05). 
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Figure 3.4: Detection of G-CSFR and phospho-STAT3 in primary ovarian 
cancer 
Immunohistochemical staining of normal ovary (A, D), benign tumor (B, E), or 
Grade 3 tumor (C, F) samples with -G-CSFR (A-C) or -pSTAT3 (D-F), as 
indicated. Arrows indicate scattered epithelial staining with both antibodies in Grade 
3 tumors, and arrowheads indicate vessel-associated staining. Immunohistochemical 
staining with -G-CSFR or -pSTAT3 was scored on a scale of 0-5, and represented 
as a scatter-plot for normal ovary, benign and pooled tumor groups, with the level of 
statistical significance indicated (ns: not significant; *: p<0.05). 
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3.3 Discussion 
The results presented in this Chapter revealed broad expression of multiple 
members of the IL-6R family and their ligands in ovarian cancer samples. The 
expression patterns could be categorised into three groups. Firstly, those in which 
both the ligand and their receptor component were expressed, namely IL-6/IL-
6R+GP130, LIF/LIFR+GP130, OSM/OSMR+GP130, IL-31/IL-
31R+OSMR+GP130 and IL-11/IL-11R+GP130. Secondly, those where the 
ligand was widely expressed but the receptor chain showed specific expression, such 
as G-CSF/G-CSFR, Leptin/OBR and CNTF/CNTFR+LIFR+GP130. Finally, those 
with broad expression of the receptor but with little expression of the ligand, such as 
CNTFR+LIFR+GP130 and IL-27R+IL-27R+GP130. Treatment with IL-6 or 
EGF altered the expression of the cytokines and their receptor chains in subtle ways. 
However, expression of the shared GP130 chain was similar, suggesting signaling 
was generally maintained. This is the first time the entire set of IL-6R family is 
analysed in ovarian cancer which adds further information to this field. 
Having identified the expression of genes encoding multiple IL-6R family 
members in ovarian cancers, the key question to be answered was: what role do these 
receptors play? IL-6/IL-6R has been widely studied in ovarian cancer and has been 
shown to enhance migration and invasion (Wang et al., 2007b, Obata et al., 1997). 
However, functional analysis of the other receptor complexes was still required. The 
observation in the case of G-CSFR of corresponding increased pSTAT3 levels 
suggest signaling is occurring, but the consequences of this signaling are unclear. 
Importantly, the identification of ovarian cancer cell lines expressing G-CSFR and 
OBR complexes provides the key reagents to commence functional studies on these 
receptors.  
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Chapter 4 ~ Functional role of G-CSFR 
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4.1 Introduction 
The vast majority of ovarian cancers arise from malignant transformation of 
either the ovarian surface epithelium (OSE) (Hudson et al., 2008) or the secretory 
cells of Fallopian tube epithelium (FTE) (Karst and Drapkin, 2010, Colombo et al., 
2010). The process by which it occurs remains poorly understood; however, it has 
been postulated the clonal expansion of OSE and/or FTE secretory cell forms a 
neoplastic precursor lesion, which ultimately gives rise to ovarian tumors (Colombo 
et al., 2010). One key event in the progression of the disease is the spread of these 
neoplastic cells into the peritoneum where they survive as cellular aggregates or 
spheroids, prior to attachment to a suitable secondary site for further growth, 
invasion and metastasis (Shield et al., 2009, Burleson et al., 2006). Tumor cells are 
known to secrete cytokines and growth factors (Zeimet et al., 1998, Punnonen et al., 
1998, Zebrowski et al., 1999), which results in autocrine and paracrine loops that are 
able to support the anchorage-independent growth of ovarian cellular aggregates and 
stimulate invasion (Shield et al., 2007, Ahmed et al., 2005). 
G-CSF principally regulates the proliferation and maturation of granulocytes 
(Solaroglu et al., 2006). It acts by binding to its receptor complex, G-CSFR, which 
leads to the activation of many signaling pathways, including the JAK2/STAT3 
pathway (Ward, 2007). G-CSF and G-CSFR are known to be expressed in many 
tumors, and have been shown to induce proliferation and invasion in several cases, 
including glioma and skin carcinoma cells in vitro (Mueller and Fusenig, 1999, Guo 
et al., 2010, Mueller et al., 1999). However, studies examining G-CSF/G-CSFR in 
ovarian cancer – and the phenotypic changes induced – have not been definitive.  
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Studies from the previous Chapter identified expression of G-CSFR on a 
subset of high-grade ovarian cancers. This is significant since its ligand G-CSF, has 
been employed to aid haematopoietic recovery following chemotherapy for a range 
of malignancies, including ovarian cancer (Bohlius et al., 2003, Ray-Coquard et al., 
2007). Therefore, the potential exists for deleterious effects from the use of G-CSF as 
part of ovarian cancer therapy in those cases where G-CSFR is expressed. Therefore, 
the Aim of this Chapter was to investigate the functional consequences of G-CSFR 
activation on ovarian cancer cells.  
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4.2 Results 
4.2.1 Expression of G-CSFR and its ligand in ovarian cancer cell lines 
Based on the results of Chapter Three, five ovarian cancer cell lines were 
chosen for further study. This included three cell lines (HEY, TOV21G, OVCA429) 
positive for G-CSFR expression, two of which (HEY, OVCA429) were also positive 
for G-CSF expression, and two cell lines (OVCA433, SKOV3) negative for G-
CSFR, with OVCA433 positive for G-CSF. All cell lines were positive for IL-6R and 
the majority also for IL-6, consistent with previous reports (Watson et al., 1990).  
FACS analysis was used to confirm that the G-CSFR expression observed by 
RT-PCR led to detectable cell-surface expression of the encoded G-CSFR (Fig. 
4.1A). Strong staining was observed with -G-CSFR antibodies in the three cell lines 
that were positive for G-CSFR expression by RT-PCR (HEY, TOV21G, OVCA429), 
but not the two RT-PCR negative lines tested (SKOV3, OVCA433). Conditioned 
media were analyzed using a G-CSF-specific ELISA, which confirmed robust 
production of G-CSF, particularly in the HEY, OVCA429 and OVCA433 cells lines 
(Fig. 4.1B), despite the latter not expressing G-CSFR, confirming the two genes are 
not co-ordinately regulated. 
4.2.2 G-CSF stimulates ovarian cancer cell migration 
Having established the cell-surface expression of G-CSFR in these ovarian 
cancer cell lines, the functional significance of this was investigated with regard to 
key cancer phenotypes. Migration was examined using a wound healing assay (Jones 
et al., 2008), which was performed either without cytokines or in the presence of G-
CSF or IL-6 as a control (Fig. 4.2A).  
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Figure 4.1: Expression of G-CSF/G-CSFR in ovarian cancer 
 A-B: Expression of G-CSF/G-CSFR in a panel of ovarian cancer cell lines. Cells 
were subjected to FACS analysis using -G-CSFR-PE (red line) or an isotype 
control (black line), or conditioned media analysed for G-CSF by ELISA (B), which 
has a standard limit of detection as 20pg/ml. 
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Figure 4.2: Phenotypic effects of G-CSF on G-CSFR-positive ovarian cancer 
cells 
A. Wound healing assay. Indicated cells were incubated in a medium lacking 
cytokines (Ctrl) or containing G-CSF (10 ng/ml) or IL-6 (10 ng/ml). Images are 
representative of single independent experiments performed in triplicate. Graphs 
represent the mean percentage area of wound closure from three independent 
experiments (n=3;*p<0.05). 
B. Transwell migration assay. Indicated cells were analysed for migration in a 
Transwell chamber in the presence and absence of G-CSF and IL-6. Mean number of 
cells migrated through the chamber was counted from 5 different areas from three 
independent experiments (n=3;*p<0.05).  
C. Proliferation assay. Indicated cells were incubated over a period of 5 days in the 
presence and absence of G-CSF (thick dotted line) and IL-6 (thin dotted line). The 
graph represents the mean cell count of three independent experiments 
(n=3;*p<0.05). 
D. Apoptosis assay. Indicated cells were treated with sodium azide alone (Ctrl) or in 
the presence of G-CSF and IL-6. Graph shows the mean percentage of apoptotic cells 
(n=3;*p<0.05). 
 
 
Chapter 4 G-CSFR in ovarian cancer 
 
70 
 
 
 
 
 
Chapter 4 G-CSFR in ovarian cancer 
 
71 
 
Migration was increased upon G-CSF stimulation in the G-CSFR-positive cell lines 
but not in the G-CSFR-negative cell lines. In contrast, IL-6 enhanced migration in 
each of the cell lines tested, all of which were IL-6R-positive. 
To determine whether the migration observed was part of a chemotactic 
response, a Transwell assay was used to measure directional cell migration. Addition 
of G-CSF again increased migration in all G-CSFR-positive cell lines (Fig. 4.2A, B). 
However, no significant difference in migration was observed whether the G-CSF 
was placed in the upper or lower chamber, suggesting G-CSF-stimulated increased 
cell migration was not chemotactic in nature. 
4.2.3 G-CSF does not affect proliferation but protects against apoptosis   
Cytokines are known to stimulate proliferation and survival in responsive 
cells. Therefore, these parameters were examined in ovarian cancer cell lines in the 
presence or absence of cytokines. IL-6 elicited a significant increase in proliferation 
in all cell lines, but no enhancement in proliferation was observed with G-CSF (Fig. 
4.2C). Possible effects of G-CSF on survival were then investigated. However, the 
cell lines tested showed very low levels of apoptosis, even in low serum, and so 
apoptosis was induced by the addition of sodium azide (0.5%) in order to evaluate 
potential anti-apoptotic responses. G-CSF was able to provide variable but 
statistically significant protection against apoptosis in all G-CSFR-positive cell lines 
(Fig. 4.2D). IL-6 also generally enhanced survival in this setting. 
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4.2.4 Downstream pathways utilized by G-CSFR  
Granulocyte colony-stimulating factor is known to activate many different 
signaling pathways, but principal amongst these is the JAK2/STAT3 pathway (Ward, 
2007). To investigate whether this was functionally important in ovarian cancer cells, 
lysates were prepared from cell lines stimulated with G-CSF, or IL-6 as a control, 
and analyzed for STAT3 activation using phospho-STAT3-specific antibodies. 
Stimulation of the G-CSFR-positive cells OVCA429, HEY and TOV21G with G-
CSF led to robust phosphorylation of STAT3, whereas the G-CSFR-negative 
OVCA433 and SKOV3 did not show STAT3 phosphorylation upon G-CSF 
stimulation (Fig. 4.3A). In contrast, all cell lines showed IL-6-induced STAT3 
phosphorylation (Fig. 4.3A). Antibodies to detect total levels of STAT3 and GAPDH 
confirmed equivalent loading in each case. To verify the integrity of the 
JAK2/STAT3 pathway in these cells, specific inhibitors for JAK2 and STAT3 were 
used in combination with cytokine stimulation. Both inhibitors effectively blocked 
STAT3 phosphorylation by both cytokines (Fig. 4.3B). The potential activation of 
ERK and AKT was also examined using phospho-specific antibodies (Fig. 4.3C). G-
CSF induced strong activation of ERK, but not AKT, in these cells, despite robust 
activation of AKT by IL-6. The addition of a JAK2 inhibitor was able to block the G-
CSF-mediated ERK activation (Fig. 4.3D), indicating it lay downstream of JAK2. To 
confirm that signaling via the JAK2/STAT3 pathway also contributed to the G-CSF-
induced phenotypes, responsive cell lines were re-analyzed in combination with the 
specific inhibitors. Both inhibitors were able to suppress G-CSF-mediated migration 
(Fig. 4.3E).  
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Figure 4.3: G-CSFR signals via JAK2/STAT3 to mediate its effects on ovarian 
cancer cells 
A. Activation of STAT3 by G-CSF. Lysates from either untreated (Ctrl) cells or 
those treated with G-CSF or IL-6 were immunoprecipitated with -STAT3 and 
analyzed by Western blot with -phospho-STAT3 and -STAT3 antibodies. The 
input lysate was analysed using -GAPDH to confirm equivalent amounts of protein 
was examined in each case. Experiments were performed thrice and blots are 
representative of one experiment. 
B. G-CSF-induced STAT3 activation is blocked by specific inhibitors of the 
JAK2/STAT3 pathway. Cell lysates were prepared from cells either untreated or 
treated with G-CSF or IL-6 with or without specific inhibitors for STAT3 (S3I) or 
JAK2 (J2I), as indicated, and analysed for STAT3 phosphorylation as per panel A. 
C-D. G-CSF-induced ERK activation and its inhibition by a JAK2 inhibitor. Cell 
lysates were prepared from untreated (Ctrl) cells or those treated with G-CSF or IL-
6, and analysed by Western blot with anti-phospho-ERK, anti-ERK, anti-phospho-
AKT, anti-AKT and anti-GAPDH (C). This analysis was repeated for OVCA429 
cells in the presence of JAK2 inhibitor (J2I) (D). 
E. Migration is blocked by specific inhibitors of the JAK2/STAT3 pathway. Wound 
closure in OVCA429 cells by G-CSF and IL-6, with or without specific inhibitors for 
STAT3 or JAK2, as indicated (n=3;*p<0.05, **p<0.005, compared to control 
untreated cells). 
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4.2.5 G-CSF stimulates STAT3-dependant transcription 
It was important to determine whether the effects of G-CSF on STAT3 
phosphorylation translated into active STAT3-mediated transcription, and so this was 
examined at several levels. Nuclear extracts were analyzed by EMSA using a STAT3 
binding site. G-CSF induced strong binding to this probe, which was also blocked by 
both JAK2 and STAT3 inhibitors (Fig. 4.4A). The expression of two STAT3-
responsive genes, CRP and BCL-2, was then examined by RT-PCR. This revealed 
strong induction of both genes by G-CSF in the G-CSFR-positive cell lines, 
OVCA429, HEY and TOV21G, but not in the G-CSFR-negative cell lines, 
OVCA433 and SKOV3 (Fig. 4.4B). This was confirmed by both qRT-PCR (Fig. 
4.4C) and Western blot analysis (Fig. 4.4D). The addition of JAK2 or STAT3 
inhibitors effectively blocked the induction of BCL2 (Fig. 4.4E), confirming it as a 
STAT3 target. 
4.2.6 Interaction between chemotherapy agents and the G-CSF/G-CSFR 
pathway   
Both cisplatin and paclitaxel are common and effective chemotherapy treatments for 
ovarian cancer patients (Bookman, 2012, Neijt et al., 2000). Hence, it was relevant to 
investigate the status of G-CSF and G-CSFR expression in response to these 
chemotherapeutic agents in ovarian cancer cells. Addition of cisplatin resulted in 
increased expression of G-CSFR (~2-4 fold) in the four cell lines tested and of G-
CSF (~2-5 fold) in three of these lines, as determined by real-time PCR (Fig. 4.5A). 
This was further confirmed by ELISA on cell supernatants, which identified 
increased levels of secreted G-CSF in two of the cell lines, albeit to a modest extent 
(Fig. 4.5B), and by FACS analysis, which showed increased levels of cell-surface G-
CSFR on the four cell lines identified by qRT-PCR, but not in SKOV3 (Fig. 4.5C).  
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Figure 4.4: Induction of STAT3 transcriptional activity by G-CSF  
A. Induction of STAT3 DNA binding by G-CSF. Nuclear extracts were prepared 
from OVCA429 cells either untreated (Ctrl) or stimulated by G-CSF or IL-6 alone 
(No Inh) or in combination with inhibitors for STAT3 (S3I) or JAK2 (J2I), as 
indicated. 
B-E. Expression of STAT3 responsive genes by G-CSF. Cells either untreated or 
treated with G-CSF (grey bar) or IL-6 (black bar) were analyzed by semi-quantitative 
RT-PCR (B), with the fold change determined by subsequent Real-Time RT-PCR (C, 
*p<0.05 compared to the control). Expression of the encoded proteins in these cells 
was determined by Western blot analysis as indicated (D). For BCL2, this analysis 
was repeated in the presence of inhibitors for JAK2 (J2I) and STAT3 (S3I) (E). 
 
 
 
 
 
 
 
 
 
Chapter 4 G-CSFR in ovarian cancer 
 
77 
 
 
 
 
 
 
 
Chapter 4 G-CSFR in ovarian cancer 
 
78 
 
Addition of paclitaxel led to a similar induction of G-CSF and G-CSFR (Fig. 4.5D-
E). The transcription factor NFκB is known to be activated by chemotherapeutic 
agents (Lagunas and Melendez-Zajgla, 2008) and to regulate genes encoding 
cytokines (Lawrence, 2009), including G-CSF (Dunn et al., 1994). Treatment with 
either cisplatin or paclitaxel induced NFκB activation (Fig. 4.5F), suggesting that it 
may be involved in the induction of G-CSF, and potentially G-CSFR.  
Cisplatin was found to enhance wound closure, to a similar extent of that 
induced by G-CSF (Fig. 4.6A). This was blocked by inhibitors of the JAK2/STAT3 
pathway (Fig. 4.6A), which were effective in this setting (Fig. 4.6B). Both cisplatin 
and paclitaxel were also able to induce significant apoptosis in these cell lines (Fig. 
4.6C-D, respectively). This could be ameliorated by treatment with G-CSF (or IL-6), 
but not in the presence of STAT3 or JAK2 inhibitors, consistent with robust 
activation of STAT3 by G-CSF in combination with either agent (Fig. 4.7A). In this 
context, ERK was also activated by G-CSF, but not AKT (Fig. 4.7B). Finally, G-CSF 
was able to induce MDR1, GST-pi and ERCC1 to various extents in all three cell 
lines tested, including in the presence of cisplatin or paclitaxel (Fig. 4.7C), 
suggesting these proteins likely contribute to the G-CSF-induced chemoresistance 
phenotype observed.  
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Figure 4.5: Interaction between chemotherapeutic agents and G-CSF/G-CSFR  
A-E. The effects of the chemotherapeutic agents cisplatin and paclitaxel on the 
expression of G-CSF/G-CSFR. The impact of 5 day chemotherapy treatment on the 
indicated ovarian cancer cell lines was determined by RT-PCR for G-CSFR and G-
CSF in response to cisplatin (A) or paclitaxel (D), analysis of cell supernatants using 
ELISA for G-CSF in response to cisplatin (B), or FACS analysis for G-CSFR 
expression in response to cisplatin (C) or paclitaxel (E) (red line: untreated, blue line: 
chemotherapy agent) or isotype control (black line). 
F. Chemotherapeutic agents activate NFκB. Cell lysates were prepared from 
OVCA433 cells treated with cisplatin (Cis) or paclitaxel (Pac) as indicated, and 
subjected to Western blot analysis with anti-phospho-NFκB, anti-NFκB or anti-
GAPDH. 
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Figure 4.6: Effects of chemotherapeutic agents on cell survival and migration  
A. Wound healing assay. Indicated cells were treated with cisplatin alone, or with G-
CSF and IL-6 treatment, in the presence or absence of inhibitors for STAT3 (S3I) 
and JAK2 (J2I). Graph shows the percentage wound closure, expressed as mean ± 
S.E.M. (*p<0.05 compared to control, #p<0.005 compared to cisplatin) 
B. Induction of STAT3 activity. Cell lysates were prepared from OVCA429, HEY 
and TOV21G cells treated with cisplatin (Cis) as indicated, and subjected to Western 
blot analysis with anti-phospho-STAT3, anti-STAT3 and anti-GAPDH. 
C-D. Apoptosis assay. Indicated cells were treated with cisplatin (C) or paclitaxel 
(D), or with G-CSF and IL-6 treatment, in the presence or absence of inhibitors for 
STAT3 and JAK2. Graph shows the percentage of apoptotic cells, expressed as mean 
± S.E.M. (*p<0.005 compared to chemotherapeutic agent). For TOV21G cells, 
cisplatin was increased to 20 μg/ml in order to achieve significant levels of apoptosis. 
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Figure 4.7: Effects of chemotherapeutic agents on downstream pathways 
Cell lysates were prepared from OVCA429, HEY and TOV21G cells treated with 
cisplatin (Cis) or paclitaxel (Pac) as indicated, and subjected to Western blot analysis 
with anti-phospho-STAT3, anti-STAT3 and anti-GAPDH (A), anti-phospho-ERK, 
anti-ERK, anti-phospho-AKT, anti-AKT and anti-GAPDH (B), or anti-MDR1, anti-
GST-pi, anti-ERCC1 and anti-GAPDH (C).  
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4.3 Discussion 
Signaling through the G-CSFR has several important functions, including 
effective mobilization of hematopoietic progenitor cells and neutrophilic 
granulocytes from the bone marrow (Christopher and Link, 2007), as well as 
stimulation of myelopoiesis (Liongue et al., 2009a, Touw and van de Geijn, 2007). 
On the basis of these properties,G-CSF is used widely to restore neutrophil numbers 
following chemotherapy, including for ovarian cancer (Ray-Coquard et al., 2007). 
Therefore, it is of strong clinical interest if G-CSF can exert additional effects on 
ovarian cancer cells. In this Chapter, the expression of G-CSFR on a panel of ovarian 
cancer cell lines was confirmed and the effects of G-CSF treatment on proliferation, 
migration and survival determined. 
The G-CSFR has previously been implicated in a diverse range of 
malignancies. In the case of hematological cancers, its pathogenic effects are 
mediated via the expression of hyperactive truncated forms, generated through either 
somatic mutation or disrupted splicing (Liongue et al., 2009b). In solid tumors, mis-
expression of both the G-CSFR and its ligand has been implicated. Thus, a 
significant proportion of invasive bladder carcinoma cells have been shown to 
express both G-CSF and G-CSFR, with subsequent autocrine signaling contributing 
to their proliferation and survival in vitro (possibly via STAT3), as well as the size of 
their induced tumors in vivo (Chakraborty et al., 2004). Both G-CSF and G-CSFR 
have also been found to be expressed in a series of Ewing’s Sarcoma patient samples 
and cell lines, with in vivo tumor growth significantly increased by G-CSF treatment 
(Morales-Arias et al., 2007). Similarly, dysplastic and squamous cell carcinomas 
(SCCs) have been shown to exhibit higher expression of G-CSF and G-CSFR than 
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normal controls (Hirai et al., 2001). G-CSF has also been demonstrated to stimulate 
the migration of tumor cells derived from patients with head and neck squamous cell 
carcinoma, with G-CSFR-positive tumors showing increased invasion (Gutschalk et 
al., 2006).  
The role of G-CSF/G-CSFR signaling in ovarian cancer has remained 
controversial. Previous reports have shown that G-CSFR is expressed on primary 
ovarian carcinomas (Brandstetter et al., 1998, Brandstetter et al., 2001, Ninci et al., 
2000, Savarese et al., 2001). G-CSF is often co-expressed in the cancer cells or 
surrounding stroma, with the potential for both autocrine and paracrine activation 
(Savarese et al., 2001). However, the importance of G-CSF expression is ambiguous, 
with one study suggesting that it does not represent an adverse prognostic factor in 
ovarian cancer (Munstedt et al., 2010), but another showing that overall survival was 
worse if present as part of a paracrine loop (Savarese et al., 2001). G-CSF has also 
been demonstrated to stimulate the proliferation of a subset of primary ovarian cells 
and cells lines (Spinner et al., 1995, Brandstetter et al., 1998, Connor et al., 1994), 
although in other ovarian cancer cells lines increased proliferation was only observed 
in synergy with EGF (Savarese et al., 2001), and in others there was either no effect 
(Savarese et al., 2001, Brandstetter et al., 2001), or indeed inhibition (Spinner et al., 
1995). Consistent with these studies, no effect of the G-CSF/G-CSFR pathway on 
ovarian cancer cell proliferation was observed. In contrast, an alternate role for G-
CSF/G-CSFR signaling was identified with respect to ovarian cancer cell migration 
and survival – including in response to chemotherapy agents. This has not been 
reported previously, but has a parallel in a recent studying that autocrine IL-6R can 
confer chemoresistance, including to cisplatin, in ovarian cancer cells (Wang et al., 
2010). Interestingly, G-CSF/G-CSFR signaling can directly enhance the motility of 
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human neutrophils (Nakamae-Akahori et al., 2006) and is essential for the directional 
migration of myeloid cells during embryonic development (Liongue et al., 2009b), 
and also plays a key role in myeloid cell survival (Ward, 2007, Eyles et al., 2006). 
The results presented in this Chapter suggest that these downstream functions can be 
‘hijacked’ by ovarian cancer cells. 
G-CSFR signaling involves several distinct downstream intracellular 
signaling cascades, including the JAK2/STAT3 pathway, which ultimately lead to 
transcriptional changes that impact on survival, proliferation, differentiation and 
migration (Liongue et al., 2009b). The effects of G-CSF/G-CSFR in augmenting 
both ovarian cancer cell migration and survival were also shown to be mediated via 
the JAK2/STAT3 pathway. It has previously been shown that G-CSF-mediated 
STAT3 activation contributes to myeloid cell survival (Ward et al., 1999a), while 
STAT3 activation has recently been shown to contribute to both migration (Yoon et 
al., 2013) and chemoresistance (Zhou et al., 2010) of solid tumors. Published work 
has also shown that chemoresistant ovarian tumors express higher levels of STAT3 
in their non-adherent population (Latifi et al., 2012), while  cisplatin treatment was 
able to generate cells with mesenchymal properties (Latifi et al., 2011). Treatment 
with either cisplatin or paclitaxel was able to enhance expression of both G-CSF and 
G-CSFR, potentially via NFκB activation, which may augment STAT3 activation 
and possibly contribute to chemoresistance. This is consistent with studies 
demonstrating that NFκB can synergise with STAT3 (Yoon et al., 2013), and that 
NFκB inhibition can increase the efficacy of paclitaxel (Mabuchi et al., 2004). 
Finally, three well established contributors to chemoresistance, the P-glycoprotein 
pump MDR1 (Goda et al., 2009), the DNA repair component ERCC1 (Kirschner and 
Melton, 2010), and the detoxifying enzyme GST-pi (Vasieva, 2011) were all induced 
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by G-CSF, providing several potential mechanisms for mediating the effects 
observed.However, cause and effect relationships need to be firmly established using 
additional approaches. 
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5.1 Introduction 
Leptin is a 16 kDa protein product of the obese gene (Tartaglia, 1997), which 
exerts its action through a specific receptor variously called the Obese Receptor 
(OBR), or Leptin receptor, encoded by the db gene (Tartaglia et al., 1995, Cioffi et 
al., 1996). OBR is a member of the IL-6R family that forms homodimers of a single 
receptor chain. However, there are six isoforms of the OBR chain, which are 
products of alternative mRNA splicing (Lee et al., 1996, Bacart et al., 2010). These 
share a common extracellular domain, which is required for ligand binding (Zhang et 
al., 1994, Ghilardi et al., 1996, Fong et al., 1998), but differ in their intracellular 
domains. The “long” Leptin receptor chain is the only one capable of inducing 
intracellular signaling through association with JAK2 (Janus kinase 2) (Baumann et 
al., 1996, White et al., 1997, Ghilardi and Skoda, 1997, Bjorbaek et al., 1997), which 
activates STAT3, MAPK’s, and MTA1/WNT1. This chain typically complexes with 
one of the five “short” receptor chains.  
OBR has a wide variety of biological roles including regulation of energy 
metabolism, appetite, bone formation and angiogenesis (Bouloumie et al., 1998, 
Huang and Li, 2000, Sierra-Honigmann et al., 1998).  High levels of leptin 
expression are observed in obese individuals (Matsuda et al., 1995), and these 
individuals have an increased risk of diabetes, fatty liver disease and cancer (Rose-
John, 2001). However, Leptin is also known to have an important role in cancer cell 
proliferation, invasion and metastasis (Somasundar et al., 2004) in several cancer 
types, including breast, hepato, and endometrial cancers (Choi et al., 2005, Saxena et 
al., 2007a, Saxena et al., 2007b, Sharma et al., 2006).  
In breast cancer, the effects of Leptin have been shown to be mediated 
through the activation of specific genes by STAT3 to produce different phenotypes: 
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cyclin D1 and c-Myc for proliferation, integrin 6 for migration and VEGF and its 
receptor for angiogenesis (Saxena et al., 2007b, Saxena et al., 2007a, Saxena et al., 
2008, Gonzalez and Leavis, 2001, Gonzalez et al., 2001). Leptin has also been shown 
to induce epithelial to mesenchymal transition (EMT) of breast cancer cells via the 
AKT/GSK3 and MTA1/WNT1 signaling (Yan et al., 2012), with EMT an early step 
during tumor metastasis.  
The results of Chapter Three suggested that Leptin/OBR pathway might also 
be important in ovarian cancer, supporting an earlier study showing that Leptin 
induced proliferation in epithelial ovarian cancer cells (Choi et al., 2005). The aim of 
this Chapter was to examine the functional consequences of the OBR expression on 
ovarian cancer cells. 
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5.2 Results 
5.2.1 Expression of OBR and its ligand in ovarian cancer cell lines 
The OBR expression was further extended to the different isoforms of the 
gene in three ovarian cancers cell lines of different types, namely PA1 
(teratocarcinoma), HEY (adenocarcinoma) and ES2 (clear cell carcinoma) (Fig 
5.1A). This revealed strong expression of the OBR long form in PA1 and HEY cell 
line, with no expression in the ES2 cell line. PA1 and HEY also expressed the OBR 
short isoform 1 and 3 (S1 and S3), but not the OBR short isoform 2 (S2). ES2 
showed very low expression of the OBR short isoform 1 (S1) but not the other two 
short isoforms. However, all the cell lines showed strong expression of the ligand, 
Leptin. Leptin treatment resulted in increased expression of the OBR long receptor 
form in HEY cells but no change in gene expression in the other cell lines. FACS 
analysis was used to confirm cell-surface expression of OBR (Fig. 5.1B), with strong 
staining observed in PA1 and HEY, but not in the ES2 cell line.  
5.2.2 Role of OBR signaling in ovarian cancer 
The functional significance of OBR expression in ovarian cancer cells was 
investigated with regard to key cancer phenotypes. Migration was examined using a 
wound-healing assay (Jones et al, 2008), which was performed either without 
cytokines or in the presence of Leptin (Fig. 5.2A). Migration of cells was found to be 
increased upon Leptin stimulation in the cell lines expressing the OBR long isoforms 
(PA1 and HEY) but not in those expressing an OBR short isoform (ES2). Whether 
the migration observed was part of a chemotactic response was explored using a 
Transwell assay to measure directional cell migration. Addition of Leptin again 
increased migration only in the OBR long-positive cell lines (Fig. 5.2B, C). 
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Figure 5.1: Expression of Leptin/OBR in ovarian cancer 
A-B: Expression of Leptin/OBR in a panel of ovarian cancer cell lines. Cells were 
analysed by RT-PCR for expression of the indicated genes (A), subjected to FACS 
analysis using -OBR-FITC (red line) or an isotype control (black line) (B). 
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Figure 5.2: Phenotypic effects of Leptin on OBR long -positive ovarian cancer 
cells 
A. Wound healing assay. PA1, HEY and ES2 cells were incubated in a medium 
lacking cytokines (Ctrl) or containing Leptin (100 ng/ml). Images are representative 
of single independent experiments performed in triplicate. Graphs represent the mean 
percentage area of wound closure from three independent experiments (B).   
C. Transwell migration assay. PA1, HEY, ES2 cells were analysed for migration in a 
transwell chamber in the presence and absence of Leptin. Mean number of cells 
migrated through the chamber was counted from 5 different areas from three 
independent experiments.  
D. Proliferation assay. Cell counts for the indicated cell lines over a period 3 days in 
the absence and presence of Leptin. The graph represents the mean of three 
independent experiments (*p<0.005). 
E. Apoptosis assay. Graph shows the mean percentage of three independent 
experiments of apoptotic cells pre- and post- Leptin treatment (*p<0.05). 
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Addition of                     Leptin again increased migration only in the OBR 
long-positive cell lines (Fig. 5.2B, C).  
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However, no significant difference in migration was observed whether the Leptin 
was placed in the upper or lower chamber, suggesting Leptin-stimulation of cell 
migration was not chemotactic in nature.  
Cytokines are also known to stimulate proliferation and survival in 
responsive cells, and so these parameters were assessed in response to Leptin 
stimulation. Leptin elicited a significant increase in proliferation in OBR long-
positive cell lines (PA1, HEY), but not in the negative line (ES2) (Fig. 5.2D). With 
respect to survival, the cell lines tested showed very low levels of apoptosis, even in 
low serum, and so apoptosis was induced by the addition of sodium azide (0.5%) in 
order to evaluate anti-apoptotic responses. Leptin provided variable but statistically 
significant protection against apoptosis in the OBR long-positive cell lines (PA1, 
HEY) but not in the negative line (ES2) (Fig. 5.2E).  
5.2.3 OBR mediates its effect in ovarian cancer cells via the JAK2/STAT3 
pathway 
Leptin is known to activate a number of different signaling pathways, including the 
JAK2/STAT3 pathway. To investigate whether the OBR expressed on the ovarian 
cancer cells was functional, cell lines were analyzed for activation of STAT3 
following Leptin. Leptin stimulation of PA1 and HEY, which both expressed the 
long form of OBR, led to a robust phosphorylation of STAT3, but not of the ES2 cell 
line, which only expressed the short receptor isoforms. Levels of total STAT3 and 
GAPDH were used to confirm equivalent loading in each case (Fig 5.3A). This 
experiment was repeated in the presence of specific JAK2 and STAT3 inhibitors 
alongside a DMSO (vehicle) control. Both inhibitors effectively blocked STAT3 
phosphorylation by Leptin in PA1 and HEY cell lines, confirming a functional 
JAK2-STAT3 pathway (Fig. 5.3B). 
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Figure 5.3: Pathways activated by Leptin/OBR in ovarian cancer  
A. Activation of STAT3 by Leptin. Cell lysates from the indicated lines either 
untreated (-) or treated with Leptin analysed by Western blot with -phospho-
STAT3 and -STAT3. The input lysate was analysed using -GAPDH to confirm 
equivalent lysate was used in each case. Experiments were performed thrice and 
blots are representative of one experiment. 
B. Leptin-induced STAT3 activation is blocked by specific inhibitors of the 
JAK2/STAT3 pathway. Cell lysates were prepared from cells either untreated or 
treated with Leptin with or without specific inhibitors for STAT3 or JAK2, as 
indicated, and analysed for STAT3 phosphorylation as per panel A.  
C-D. Expression of STAT3 responsive genes by Leptin. Cells either untreated or 
treated with Leptin were analysed by semi-quantitative RT-PCR (C), with the fold 
change determined by subsequent Real-Time RT-PCR (D) (*p<0.05).  
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Figure 5.4: Effects of Leptin/OBR on cell survival and migration are mediated 
via the JAK2/STAT3 pathway 
A. Wound healing assay. Percentage of wound closure for cells untreated or with 
Leptin treatment, in the presence or absence of inhibitors for JAK2 (J2I) and STAT3 
(S3I) (mean ± S.E.M; *p<0.05;**p<0.05 compared to Leptin treated).  
B. Proliferation assay. Cell counts for the indicated cell lines over a period of 3 days 
in the presence or absence of Leptin and also in the presence or absence of inhibitors 
of JAK2 (J2I) shown in red dotted line and STAT3 (S3I) shown in purple dotted line. 
The graph represents the mean of three independent experiments.  
C. Apoptosis assay. Percentage of apoptotic cells when treated with sodium azide 
alone, or with Leptin treatment, in the presence or absence of inhibitors for STAT3 
and JAK2 represented as mean ± S.E.M (n=3; *p<0.05 compared to untreated; 
**p<0.05 compared to Leptin treated). 
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Since OBR was signaling via the JAK2/STAT3 pathway the expression of 
STAT3 responsive genes following Leptin stimulation was examined using semi- 
quantitative RT-PCR. The genes encoding the following proteins were chosen based 
on their involvement downstream Leptin: ICAM1, MMP2 and MMP9 for migration, 
BCL2 for survival and c-MYC and CCND1 for proliferation. Leptin treatment 
increased the expression of each of these genes in the cell lines expressing the long 
OBR form (PA1 and HEY), but produced no change in the negative line (ES2), with 
-ACTIN was used as a control (Fig 5.3C). This was quantified by subsequent Real-
Time RT-PCR (Fig 5.3D).  
To confirm that the signaling of the JAK2-STAT3 pathway also contributed 
to the Leptin-induced phenotypes, responsive cell lines were re-analysed in 
combination with specific inhibitors. Both the JAK2 and STAT3 inhibitors were able 
to suppress Leptin-mediated migration (Fig 5.4A), proliferation (Fig 5.4B) and 
survival (Fig 5.4C).  
5.2.4 OBR-induced Mesenchymal to Epithelial changes in PA1 teratocarcinoma 
cells  
Distinct morphological changes were observed in PA1 cells following long 
term Leptin treatment (2 days) but not in HEY or ES2 cells (Fig 5.5A).  These 
Leptin-treated PA1 cells became tightly packed, cobblestone-like, with little 
intercellular space; this represents an epithelial phenotype, clearly distinct from their 
initial fibroblast-like mesenchymal appearance. This observation suggested that 
Leptin was inducing a mesenchymal to epithelial transformation (MET). To confirm 
this expression, specific epithelial and mesenchymal markers was examined with or 
without Leptin. Long term treatment of PA1 cells with Leptin for 2 days, resulted in 
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a significant decrease in the expression of the mesenchymal markers, N-cadherin and 
vimentin, and an increase in the expression of the epithelial marker, E-cadherin by 
Real Time PCR (Fig 5.5B). There was also an increase in the expression of the pro-
epithelial transcription factor SNAIL and a decrease in the expression of the pro-
mesenchymal transcription factor SLUG. These long term Leptin-induced changes in 
expression were confirmed at the protein level, this time in the presence and absence 
of JAK2 and STAT3 inhibitors. Western blot analysis confirmed long term Leptin-
induced increased expression of epithelial proteins at the expense of mesenchymal 
markers relative to GAPDH (Fig 5.5C). Treatment with inhibitors to JAK2 and 
STAT3 prevented these changes suggesting the involvement of the JAK2/STAT3 
pathway downstream of OBR in mediating these alterations. Long term Leptin 
treatment also suppressed short term Leptin-mediated migration of PA1 (Fig. 
5.4D,E), confirming MET transformation. 
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Figure 5.5:  Induction of MET by Leptin  
A. PA1 and HEY cells were treated with Leptin (100 ng/ml) for 2 days or untreated. 
Morphological changes associated with MET are shown in phase-contrast images are 
shown by arrow marks. 
B-C. Expression of MET – responsive genes by Leptin. PA1 cells either untreated or 
treated with Leptin for 2 days with the fold change determined by subsequent Real-
Time RT-PCR with line representing the control (B). Leptin-induced MET activation 
was blocked by specific inhibitors of the JAK2/STAT3 pathway. Cell lysates were 
prepared from cells either untreated or treated with Leptin for 2 days with or without 
specific inhibitors for STAT3 or JAK2, as indicated, and analyzed for change in 
expression of MET markers and the expression determined using Western blot 
analysis (C) as per panel B (*p<0.05 compared to control).  
D-E. Analysis of PA1 cells following long term treatment with Leptin for migration 
(D) and proliferation (E). 
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5.3 Discussion 
Obesity is considered an important etiological factor for cancer that is 
associated with increased incidence of many common types of cancers (Calle et al., 
2003). However, the mechanism by which obesity contributes to cancer remains less 
clear. Elevated levels of Leptin are observed in obese individuals (Sauter et al., 2004) 
while epidemiological and in vitro studies have found a correlation between obese 
individuals expressing high Leptin levels and risk of breast or prostate cancers (Falk 
et al., 2006, Stattin et al., 2001). Other studies have shown that increased Leptin 
levels leads to an increased incidence of prostate, breast and endometrial cancer (Yin 
et al., 2004, Somasundar et al., 2004, Garofalo and Surmacz, 2006, Giovannucci et 
al., 2003, Mor et al., 2005).  
Leptin signaling via OBR has a wide variety of roles in regulating energy 
metabolism, appetite regulation, bone formation and angiogenesis (Bouloumie et al., 
1998, Huang and Li, 2000, Sierra-Honigmann et al., 1998). The long OBR isoform 
achieves this by initiating downstream signal cascades, including the JAK2/STAT3 
pathway. Numerous studies have shown that Leptin signaling can induce cancer cell 
adhesion, proliferation, survival and migration (Carino et al., 2008, Chen et al., 2007, 
Li et al., 2012b, Tanaka and Umesaki, 2008, Yuan et al., 2013, Somasundar et al., 
2004, Sharma et al., 2006, Saxena et al., 2007a, Saxena et al., 2008). However, its 
role in ovarian cancer has not been well understood.  
One study has demonstrated that Leptin/OBR signaling could induce 
proliferation of ovarian cancer cells via the MAPK pathway (Choi et al., 2005). 
Consistent with that study, results from this Chapter also identified a role for 
OBR/Leptin in inducing proliferation, although mediated via the JAK2/STAT3 
pathway.  Importantly, the MAPK pathway typically lies downstream of JAK2 and 
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so is likely blocked with the JAK2 inhibitors used in this study, and may still play a 
role. However, since Leptin-induced proliferation was also abrogated with a STAT3 
inhibitor, it appears that alternate pathways to MAPK also exist.  
Leptin was previously shown to induce cancer cells migration via the MAP 
kinase in prostate cancer (Frankenberry et al., 2004), via the AKT pathway in 
endothelial cells (Goetze et al., 2002), via the JAK/STAT, PI3K/AKT, and MAPK 
pathways in hepato cellular carcinoma cells (Saxena et al., 2007a), and via the NF-
B pathway in glioma cells (Yeh et al., 2009). This Chapter also identified 
OBR/Leptin induced migration signaling pathway in ovarian cancer cells via the 
JAK2/STAT3. In addition, a novel role in the survival of ovarian cancer cells, also 
mediated via JAK2/STAT3, was identified. This suggests that inhibitors targeting 
these molecules may be useful for the management of clinical ovarian cancer. 
Studies in breast cancer have shown Leptin is able to induce another 
phenotypic change, epithelial to the mesenchymal transition (EMT), involving 
AKT/GSK3 and MTA1/WNT1 pathways (Yan et al., 2012). However, the results in 
this Chapter showed Leptin could instead induce a mesenchymal to epithelial 
transition (MET) of ovarian teratocarcinoma-derived PA1 cells. MET is a process 
that converts motile mesenchymal cells to polarized epithelial cells, a physiological 
example of cell plasticity that occurs for example during kidney development 
(Bryant and Mostov, 2008). MET is associated with an up-regulation of epithelial 
markers, such as E-cadherin and SNAIL and a down regulation of mesenchymal 
markers such as N-cadherin, Vimentin and SLUG, which was also seen in Leptin 
treated PA1 cells, confirming that MET was occurring. MET has been shown to 
decrease cancer cell proliferation, migration and chemo-resistance, acting as anti-
tumorigenic process in melanoma cells under hypoxic conditions (Moen et al., 2009, 
Chapter 5 OBR in ovarian cancer 
 
108 
 
Na et al., 2009). These data suggest that Leptin has the potential to act as an anti-
tumorigenic agent in these cases through induction of MET change. Whether this is 
restricted to teratocarcinoma cells remains to be determined. Leptin-induced MET 
was also blocked by JAK2/STAT3 inhibitors, indicating the JAK2/STAT3 pathway 
was also utilized to mediate this process. JAK2/STAT3 inhibitors would potentially 
be counter-indicated in such cases. 
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6.1 Overview 
Ovarian cancer and its molecular etiology remain poorly understood. 
Previous research has suggested growth factors and cytokines might play a role, with 
several studies identifying expression of cytokine receptors (and their ligands) in 
ovarian cancer (Burke et al., 1996, Ninci et al., 2000, Choi et al., 2005). However, 
few studies have investigated either the functional consequences, nor the downstream 
signaling pathways responsible.  
The work described in this Thesis has provided a comprehensive analysis of 
the expression of the IL-6R family in a panel of ovarian cancer cell lines, including 
the possible involvement of autocrine loops, and confirmed expression of key 
ligand/receptor pairs in relevant clinical samples. It has also further shown that both 
G-CSFR and OBR complexes signal via the downstream JAK2/STAT3 pathway in 
ovarian cancer cells to facilitate a number of key cancer phenotypes.  These results 
have provided new insights into ovarian cancer that have therapeutic implications. 
6.2 Expression of IL-6R family members  
Based on previous studies implicating individual IL-6R family members in 
ovarian cancer cells, Chapter Three investigated the expression of all IL-6R family 
components and their ligands in a panel of ovarian cancer cell lines, with 
confirmation studies for a subset of these in relevant clinical samples. This revealed 
broad expression of several members of the IL-6R family, as well as their ligands, in 
ovarian cancer cells.  
Expression of the IL-6R complex was observed in the majority of ovarian 
cancer cells lines irrespective of their types, with the co-expression of IL-6 in most of 
these lines, consistent with previous studies on the expression status of IL-6/IL-6R in 
Chapter 6~ General discussion 
 
111 
 
ovarian cancer (Shinriki et al., 2009, Rath et al., 2010, Colomiere et al., 2009). The 
majority of ovarian cancer cell lines also expressed OBR, OSMR and LIFR while 
three of five adenocarcinoma ovarian cancer cell line expressed G-CSFR, in line with 
other studies (Savarese et al., 2002, Choi et al., 2005, Ninci et al., 2000), with LIF, 
G-CSF and Leptin being expressed more widely than OSM. Variable expression of 
other members of the IL-6R family, namely CNTFR, IL-27R, IL-31R, IL-11R was 
also observed, with a similar result for their respective ligands, except for IL-27 
which was not expressed in any of the lines. These represent the first analysis of 
these four cytokine/receptor pairs in ovarian cancer. 
Previous studies suggested that cytokine receptor expression levels could be 
altered in response to cytokines and growth factors (Colomiere et al., 2009, Xu et al., 
2010, Zeineldin et al., 2010). Therefore, the expression of IL-6R family members 
and their ligands was also analysed following the addition of an exogenous cytokine, 
namely IL-6, and growth factor, EGF. The overall pattern of expression was largely 
similar to that of the unstimulated cells, although individual receptors/ligands were 
altered, particularly in some cell lines.  
The expression of cytokine receptors on tumor cells has the potential to 
impact on the migration, proliferation and survival of these cells. Therefore, it was 
important to verify the expression data in primary ovarian cancer samples. These 
were analysed for expression of selective cytokine/receptor pairs, namely IL-6/IL-
6R, LIF/LIFR, G-CSF/G-CSFR, Leptin/OBR and CNTF/CNTFR. This confirmed 
the robust expression of these cytokines/receptor pairs in Grade 3 ovarian cancer 
samples compared to benign and normal samples. Finally, the expression of G-CSFR 
was also confirmed on tissue sections due to the availability of a suitable antibody 
against -G-CSFR. STAT3 phosphorylation was observed in tissue sections 
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expressingG-CSFR, providing preliminary evidence that active signaling was 
occurring in these cells. 
6.3 Functional role of G-CSFR in ovarian cancer  
Chapter Four focused on the functional consequences of G-CSFR expression 
in ovarian cancer cells. Aberrant G-CSFR signaling has been implicated in a range of 
other malignancies including small-cell lung carcinoma (Avalos et al., 1990), 
astrocytoma (Kikuchi et al., 1996) and primary bladder cancer (Lindemann et al., 
1988, Dong et al., 1993, Tachibana et al., 1995). Moreover, G-CSF is used clinically 
following ablative therapies for a variety of solid tumors, including ovarian cancer 
(Vial and Descotes, 1995, Nieboer et al., 2001), providing additional clinical 
relevance. 
Stimulation of G-CSFR-positive ovarian cancer cells with G-CSF resulted in 
increased migration and survival, including against chemotherapy-induced apoptosis 
indicating the G-CSFR complexes were functional and augmented key cancer 
phenotypes. G-CSFR utilizes several signaling pathways in hematopoietic cells, 
including the RAS/MAPK, PI3K/AKT and JAK1-2/STAT3 modules (Carvalho et 
al., 2011, Avalos, 1996). The phenotypic effects of G-CSFR activation in ovarian 
cancer cells was shown to be mediated by signaling through the downstream 
JAK2/STAT3 pathway. This is consistent with the role of G-CSFR-mediated 
activation of STAT3 in hematopoietic cells, especially with regard to increased 
survival (Liongue et al., 2009b).  
G-CSF is commonly used in the context of ovarian cancer to restore 
neutrophils ablated by standard chemotherapy (Yamada et al., 2001). However, if the 
tumor expresses G-CSFR, then clearly G-CSF treatment could actually contribute to 
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tumor development by increasing migration and/or survival, irrespective of 
endogenous G-CSF expression. This is consistent with G-CSFR expression status 
having poor prognosis in oral, colon and pharyngal cancer (Tsuzuki et al., 1998, 
Yang et al., 2005a). Importantly, aberrant G-CSFR signaling was actually found to 
be enhanced by both cisplatin and paclitaxel in a number of ovarian cancer cell lines, 
underlying the need for caution with regard to G-CSF therapy.  
Indeed, the results of Chapter Four suggest that it is prudent to re-evaluate G-
CSF therapy in ovarian cancer, particularly in patients bearing G-CSFR-positive 
tumors. Therefore, screening ovarian tumors for G-CSFR expression – by histology, 
FACS or Next Gen sequencing approaches – could be beneficial prior to 
administration of G-CSF, potentially indicating alternative therapies for patients with 
G-CSFR-positive tumors. Of relevance, co-administration of granulocyte-
macrophage colony-stimulating factor and recombinant interferon gamma 1b in 
concert with carboplatin treatment in women with recurrent ovarian cancer was 
shown to be efficacious and elicited a favourable hematological profile (Schmeler et 
al., 2009), providing a potential alternative option in this regard.  
6.4 Role of OBR in ovarian cancer 
Chapter Five examined the role of OBR in ovarian cancer. Epidemiological 
data have shown a positive correlation between obesity and cancer growth, with 
obese individuals having a poorer prognosis (Dieudonne et al., 2002, Reeves et al., 
2007, Renehan et al., 2008). The biological mechanisms underlying the relationship 
between obesity and cancer are not well understood. However, obesity is associated 
with high levels of Leptin (Flier, 1998), which has also been shown to stimulate 
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proliferation on a range different of cancers (Pai et al., 2005, Choi et al., 2005, Hu et 
al., 2002).  
Chapter Five demonstrated various OBR isoforms were expressed in cell 
lines representing different types of ovarian cancer. However, the long isoform of 
OBR that is capable of intracellular signaling was only expressed on the 
adenocarcinoma and teratocarcinoma subtypes. In these OBR positive cancer cell 
lines, lines short-term treatment with Leptin increased migration and proliferation, 
and also protected the cells from undergoing apoptosis. Use of specific inhibitors 
confirmed that each of these phenotypes was mediated by JAK2/STAT3 pathway. 
One previous study has shown that OBR signalled via ERK1/2 to induce 
proliferation of ovarian cancer cells (Choi et al., 2005). This Chapter demonstrated 
that signaling via the JAK2/STAT3 pathway also contributes to OBR-stimulated 
proliferation, but also to the other phenotypes. 
The teratocarcinoma cell line was also found to undergo a mesenchymal to 
epithelial (MET) transition in response to long-term Leptin treatment, confirmed by 
altered expression of specific markers. This transition was also JAK2/STAT3 
dependent.  MET is a process that can allow cancer cells to stabilise at a distant 
metastatic site by regaining important phenotypic properties (Yang and Weinberg, 
2008). However, studies have also shown that tumors that have undergone MET 
showed decreased migration and proliferation, as well as increased apoptosis, 
resulting in increased susceptibility to chemotherapeutic agents (Gunasinghe et al., 
2012, Chaffer et al., 2007). Therefore, there is a possibility that Leptin treatment in 
this context may in-fact be beneficial.  
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Chapter Five has added to our understanding of the role of OBR in ovarian 
cancer, potentially throwing some light on the link between obesity and cancer. This 
Chapter also suggested that Leptin mediated OBR signaling via the JAK2/STAT3 
pathway could potentially be pro-tumorigenic or an anti-tumorigenic in ovarian 
cancer depending on the cell context. 
6.5 Future directions 
The results presented in this Thesis suggest that further investigation into 
aberrant cytokine receptor signaling in cancer is warranted. 
6.5.1 Further analysis of G-CSFR and OBR 
To delineate a functional role for G-CSFR and OBR in key cancer 
phenotypes in vivo studies in mice would be informative. Xenografts of genetically 
manipulated (enforced cytokine receptor expression or cytokine receptor 
knockdown) ovarian cancer cells could be orthotopically transplanted into the 
ovaries of SCID mice, which mimics the peritoneal invasion of ovarian carcinoma 
observed in patients (Steinkamp et al., 2013). The mice could then be sacrificed, with 
the ovaries and surrounding organs evaluated for relative extent of spread and size of 
the xenografts. These mice could also be treated with rh G-CSF and rh Leptin as 
appropriate to delineate the effects of increase ligand levels on cancer development. 
Such experiments could be extended to include mice in which endogenous G-CSF 
and Leptin genes were knocked-out to distinguish between systemic and local 
effects. Alternatively, patient derived xenografts with different levels of receptor 
expression could be assayed in a similar manner. 
Ultimately, clinical trials are necessary to definitively assess the roles of G-
CSFR and OBR in ovarian cancer etiology. In particular, analysis of the tumor G-
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CSFR status of patients receiving G-CSF as a part of their chemotherapeutic regime 
and its association with prognosis is urgently required. Similar analyses combining 
OBR status, Leptin levels, obesity indicators and clinical outcomes in ovarian cancer 
would also be informative.  
6.5.2 Role of other IL-6R family members in ovarian cancer 
Chapter Three demonstrated that multiple members of the IL-6R family were 
expressed in ovarian cancer. Therefore, it would also be of interest to extend the 
functional studies to other family members that also have relevance to ovarian 
cancer. Of particular priority would be a detailed study on the role of IL-23R and IL-
11R. 
Interleukin-23 receptor (IL-23R) is complex of interleukin-12 receptor 1 
(IL12R1) and IL-23R (Parham et al., 2002), which is known to exert pro-
inflammatory function (Vignali and Kuchroo, 2012). IL-23R has been studied in 
range of cancers, where it has been shown to induce cancer cell proliferation (So et 
al., 2013, Fukuda et al., 2010, Langowski et al., 2006). In lung cancer cells these 
proliferative responses have been shown to be mediated by the JAK2/STAT3 
pathway, with JAK2 inhibitors able to block these effects (So et al., 2013). However, 
other studies have shown that high concentrations of IL-23 can inhibit lung cancer 
cell growth, suggesting that IL-23 may have potential anti-tumor properties (Baird et 
al., 2013). Similarly, IL-23 has been found to be overexpressed in ovarian cancer, 
with a positive correlation between expression and overall survival (Wolf et al., 
2010). Moreover, polymorphisms in the IL-23R gene have been associated with late 
stage ovarian cancer in Chinese, suggesting a role in disease susceptibility (Zhang et 
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al., 2010). Therefore, a detailed study of the role of IL-23/IL-23R expression in 
ovarian cancer is required to understand its precise role. 
The receptor complex for IL-11 consists of a heterodimer of IL-11R and 
GP130 that also signals via the JAK2/STAT3 pathway (Dimitriadis et al., 2006, 
Wang et al., 2007a). IL-11R signaling supports the growth of multiple hematopoietic 
progenitors as well as exerting metabolic and cytoprotective effects on cells outside 
the hematopoietic system (Nandurkar et al., 1998). IL-11 has been shown to regulate 
adhesion and migration of chondrosarcoma (Li et al., 2012a) and endometrial cancer 
via STAT3 (Lay et al., 2012), and was recently demonstrated to be the dominant 
cytokine in the etiology of gastrointestinal cancer (Putoczki et al., 2013). A previous 
study has shown that IL-11R is expressed on the majority of ovarian cancer cells, 
with expression of its ligand much less common (Campbell et al., 2001), consistent 
with the data in Chapter Three. However, the function of IL-11/IL-11R signaling in 
ovarian cancer remains uncertain. This is of clinical relevance, since IL-11 is being 
developed as a treatment for chemotherapy-induced thrombocytopenia (Wu et al., 
2012). 
6.5.3 Role of other cytokine receptors in ovarian cancer 
There exist a large number of cytokine receptors, of which the IL-6R family 
members represent just a small component. Several of the other cytokine receptors 
share similar pathways and cellular roles to the IL-6R family, and have also been 
implicated in cancer, meaning that they are also of potential interest. Two examples 
are the erythropoietin receptor (EPOR) and the IL-4R. 
EPOR is a homodimeric receptor that activates JAK2/STAT5 to promote 
erythroid progenitor survival, proliferation, and differentiation (Wojchowski et al., 
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1999). As a consequence, erythropoietin (EPO) is used to increase red blood cell 
counts in cancer patients following chemotherapy (Filip et al., 1999). However, 
recent studies have reported reduced survival in patients receiving both EPO and 
chemotherapy, potentially related to EPO-induced cancer progression (Miyake et al., 
2013). EPO has also been shown to induce growth in prostate cancer cells via 
STAT5 (Feldman et al., 2006).  Both EPO and EPOR have been identified in the 
female reproductive tract, including the ovary (Yasuda et al., 1998, Yasuda et al., 
2001a). EPOR is frequently expressed on ovarian tumors and cell lines (McBroom et 
al., 2005, Jeong et al., 2008). Long-term EPO treatment of patients expressing 
EPOR-positive ovarian tumors led to increased resistance to paclitaxel or cisplatin 
(Solar et al., 2008), while targeting the EPOR resulted better shrinkage of the tumors 
(Yasuda et al., 2001b). However, the exact mechanism through which EPOR 
signaling mediates these effects remains unclear. Further studies in ovarian cancer 
cells could provide important insights to inform clinical practice.  
There exist two alternate receptors for IL-4, one a heterodimer of IL-4Rand 
the c chain, and the other a heterodimer of IL-4Rand IL-13R1 (LaPorte et al., 
2008). These activate several signaling molecules, notably including JAK1 and 
JAK3, which in turn activate STAT6 (Ihle, 1995, Pernis et al., 1995). IL-4R 
signaling is known to modulate proliferation of B-cells (Nelms et al., 1999). Previous 
studies have shown IL-4R is expressed on solid tumors including lung and breast 
carcinoma (Obiri et al., 1994). Both in vitro and in vivo experiments on cancer cells 
have shown that IL-4 can function as an immune-modulating anti-tumor agent (Toi 
et al., 1992, Topp et al., 1995a, Topp et al., 1995b). However, IL-4 has also been 
shown to play a major role in tumor progression on human cancer cells expressing 
IL-4R (Li et al., 2009, Burt et al., 2012). Ovarian tumors have been shown to express 
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IL-4R, which switches on multiple signaling pathways upon ligand binding (Kioi et 
al., 2005). However, the role of IL-4R signaling in ovarian cancer is not well 
understood, and studies examining potential anti-tumor versus pro-tumor functions 
are worthwhile. 
6.5.4 Role of IL-6R family in other cancers 
A number of studies have described a role for altered signaling from various 
IL-6R family members as a contributing factor to a range of malignancies, including 
solid tumors. For example, LIF acts as a growth promoting factor in pancreatic 
carcinoma (Kamohara et al., 2007), both IL-6 and OSM are able to stimulate 
proliferation of prostate cancer cells (Godoy-Tundidor et al., 2005), while G-CSF has 
similar roles in leukemia (Katayama et al., 1998) and squamous cell carcinoma 
(Hirai et al., 2001). Autocrine activation appears to play a key role, as described for 
IL-6/IL-6R in a variety of tumors (Grivennikov and Karin, 2008), while high 
expression of Leptin is observed in prostate cancer patients (Stattin et al., 2001). 
However, there has been no systematic study and the roles of individual receptors in 
many of these cancers. Hence, exploring the role of IL-6R family members in these 
cases is warranted. Indeed the recent clinical development of JAK2 and STAT3 
inhibitors (Lin et al., 2010b, So et al., 2013), enabling the targeting of multiple IL-6R 
family members in essentially any cancer setting, provides even more impetus for 
these studies.  
6.6 Therapeutic implications 
 The results presented in this Thesis have clear implications for the clinic, 
especially with regard to the use of cytokines as a part of therapy, and the potential 
therapeutic targeting of cytokine receptor pathway components.  
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6.6.1 Cytokine therapy 
The standard treatment for ovarian cancer patients remains maximal surgical 
cytoreduction followed by platinum and taxane based chemotherapeutic regimes with 
cytokines often used as supportive agents (Fanning et al., 2000). Of particular 
relevance is IL-6 which is used as part of photodynamic therapy (Wei et al., 2007), 
while G-CSF has been extensively employed to aid hematopoietic recovery 
following chemotherapy for a range of cancers, including those of an ovarian nature 
(Bohlius et al., 2003, Ray-Coquard et al., 2007). However, it is clear from previous 
studies that aberrant signaling from cytokine receptors, such as IL-6R (Matsuo et al., 
2003, Rath et al., 2010, Wang et al., 2012) and G-CSFR (this study) can contribute to 
ovarian cancer etiology. Therefore, pre-screening patients for the expression of these 
receptors would be highly recommended prior to administration of the respective 
cytokine, potentially indicating alternative approaches for these patients.  
6.6.2 Pathway specific inhibitors 
Multiple molecular targets are currently being explored as alternative 
treatments, including growth factor receptors and their downstream signal 
transduction pathways, as well as cell cycle regulators (Wright et al., 2006, Posadas 
et al., 2007, Bhattacharya et al., 2008). Given that aberrant activation of IL-6R 
family members appears to contribute to ovarian cancer progression via the 
JAK1/2/STAT3 pathway (Catlett-Falcone et al., 1999, Grivennikov et al., 2009, 
Hodge et al., 2005, Hong et al., 2007), specific therapeutics targeting this pathway 
are also likely to be applicable to ovarian cancer.  
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6.6.2.1 Cytokine/receptor inhibitors 
 Antibodies have been developed that specifically target either IL-6 or IL-6R 
to block their activity. These therapies have been shown to inhibit tumor growth in 
patients either alone or in combination with cytotoxic chemotherapies in a range of 
carcinomas. For example, an IL-6 ligand-blocking antibody (CNTO-328) has been 
used in a number of phase I/II clinical trials, including myeloma, breast, prostate and 
ovarian cancer (Trikha et al., 2003, Voorhees et al., 2007, Garcia-Tunon et al., 2005, 
Voorhees et al., 2009, Tomillero and Moral, 2009, Wallner et al., 2006, Dorff et al., 
2010, Puchalski et al., 2010). Similarly, an anti-IL-6 antibody (Siltuximab) was 
shown to decrease ovarian tumor proliferation in a xenotransplantation model 
(Coward et al., 2011). An IL-6R blocking antibody (tocilizumab), which binds to the 
ligand binding site of human IL-6R and so inhibits IL-6 binding, has recently been 
approved for Castelman's disease and rheumatoid arthritis (Nakashima et al., 2010, 
Garnero et al., 2010), providing an additional option in this regard. Given the results 
of this Thesis, the development of inhibitory anti-G-CSFR and anti-OBR would also 
provide an attractive option for ovarian cancer therapy. 
6.6.2.2 JAK2/STAT3 Inhibitors 
A number of JAK2 and STAT3 inhibitors have now been developed and used 
in clinical trials for various diseases, such as multiple lymphoma (Younes et al., 
2012), prostate cancer (Shodeinde and Barton, 2012), renal cancer (Rossi et al., 
2010) and psoriasis (Papp et al., 2012). Inhibition of this pathway has already shown 
promise in the context of ovarian cancer. For example, inhibition of JAK2/STAT3 
with diindolylmethane induced apoptosis in ovarian tumors (Kandala and Srivastava, 
2012). In addition, the JAK inhibitor AZD1480 was able to increase the chemo-
sensitivity of ovarian cancer cells lines by inhibiting STAT3 signaling induced by 
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IL-6 and oncostatin M (Hedvat et al., 2009), while inhibition of STAT3 activation by 
siRNA led to reversal of paclitaxel resistance in ovarian cancer cell lines (Lee et al., 
2011). The JAK-STAT pathway has also been implicated in ‘cancer stem-like cells’ 
(Kiger et al., 2001), making the use of such inhibitors even more enticing, as they 
may eliminate the cell population that facilitates the development of recurrent 
tumors. Therefore, inhibitors of the JAK2/STAT3 pathway holds considerable 
promise as a future therapeutic agents in ovarian cancer. 
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epithelial to mesenchymal transition in 
vivo  
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A.1 Introduction 
 EMT potentially plays a role in cisplatin-induced resistance in ovarian 
carcinomas (Wang et al., 2009). Cisplatin was able to enhance activation of ERK2 
and induced EMT and CSC-like phenotypes in ovarian cancer cells in vitro. 
Inhibition of ERK2 activation with a specific MEK inhibitor resulted in the partial 
suppression of EMT and CSC (Latifi et al., 2011). This Appendix describes studies 
that sought to confirm these results in vivo using a zebrafish xenotransplantation 
model.  
A.2 Results 
A.2.1 Cisplatin enhanced the migratory potential of ovarian cancer cells in vivo 
To confirm the in vivo relevance of cisplatin-induced EMT, an established 
zebrafish xenotransplantation model of metastatic behaviour was employed. Cells 
were fluorescently labelled prior to injection into the yolk sac of 2-day-old zebrafish 
embryos and visualized by confocal microscopy. Distinct fluorescent cells were 
observed from 12 hours post injection (hpi) predominantly in the tail region (Fig. 
A.1A, A.1B), in a pattern similar to that observed with pancreatic tumor cells 
(Marques et al., 2009). Cell migration into the tail was analyzed and quantified at 
both 24 and 48 hpi (Fig. A.1A). In three independent experiments, the average 
numbers of cisplatin-induced EMT transformed cells migrating towards the tail of 
zebrafish were significantly more than for the control untreated cells (Fig. A.1.A).  
A.2.2 ERK inhibition blocks the effects of cisplatin treatment 
Inhibition of ERK2 with the MEK inhibitor U0126 significantly reduced the 
migration of cisplatin-treated cells to below the basal levels (Fig. A.1.A). 
 188 
 
 
 
 
 
 
 
 
 
Figure A.1: Xenotransplantation of ovarian cancer cells in zebrafish embryos 
The migratory ability of control untreated and cisplatin-treated OVCA 433 cells was 
evaluated by xenotransplantaion in zebrafish. Zebrafish embryos were injected with 
CM-Dil labeled OVCA433 cells that were untreated, treated with cisplatin or treated 
with cisplatin and the MEK inhibitor U0126, and the tail region imaged at 0 and 
48 hpi, with manual quantification of fluorescent cells in the tail region of zebrafish 
performed at 24 and 48 hpi (A). Autofluorescence (yellow arrows) was observed in 
all embryos, primarily in the yolk, pigment cells, and the eye, with xenotransplanted 
cells evident in the tail region (blue arrows) and at the site of injection in the yolk sac 
(pink arrows) (B). Significant differences between cisplatin-treated cells compared to 
control untreated cells are indicated: *p < 0.05. 
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A.3 Discussion 
 Using a robust in vivo xenotransplantation model, these experiments 
demonstrated enhanced migratory ability of cisplatin-treated ovarian cancer cells. 
The enhanced migration of cisplatin-transformed cells in zebrafish likely reflects an 
increased metastatic ability of these cells. These results are consistent with other 
animal models where only a small subset (∼2%) of metastatic cells has been shown 
to survive and colonize at distant sites (Weiss, 1990). Since pre-treatment with the 
MEK inhibitor U0126 was able to inhibit the migration of cisplatin-transformed 
cells, it appears that ERK plays a critical role in cisplatin-induced EMT in vivo, 
supporting the in vitro studies. Moreover, the assessment of the migratory and 
invasive abilities of tumor cells in this zebrafish model provides a complementary 
approach to long-term and more expensive mouse models, and is likely to be 
valuable in evaluating the therapeutic efficacy of novel agents generally. 
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